[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 80 of about 80
1. Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, Saito K, Yoshida J: Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg; 2007 Aug;107(2):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A.
  • OBJECT: Analysis of meningiomas supports the suggestion that loss of heterozygosity (LOH) of chromosome arm 1p plays an important role in malignancy.
  • The aim of this study was to identify genes related to meningioma progression from the benign state to the atypical and anaplastic states by examining 1p LOH and the promoter methylation of RASSF1A and p73.
  • METHODS: The authors studied 40 surgical specimens (22 WHO Grade I, 11 Grade II, and seven Grade III) obtained in 37 patients with meningioma.
  • CONCLUSIONS: Based on the hypothesis that meningiomas cumulatively acquire genetic alterations and thus progress from the benign to the atypical and anaplastic states, genetic alterations in the methylation status of p73 or RASSF1A along with 1p LOH may result in the malignant transformation of a meningioma.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. DNA-Binding Proteins / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / genetics. DNA Methylation. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695396.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


2. Yang X, Gao X, Wang S: Primary mediastinal malignant meningioma. Eur J Cardiothorac Surg; 2009 Jul;36(1):217-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal malignant meningioma.
  • Primary ectopic meningiomas are extremely rare tumors of controversial origin and they are usually limited to the head and neck region.
  • There has not been any official report regarding primary mediastinal malignant meningioma until today.
  • Because of its rarity and potential value, we report here a case of primary mediastinal malignant meningioma, which turns out to be the first reported case of this type of meningioma.
  • The clinical features, treatment plans, pathological findings, as well as prognosis of a case of primary mediastinal malignant meningioma were carefully analyzed and the literature on ectopic meningioma was reviewed.
  • The diagnosis of ectopic meningioma can only be established based on microscopic and immunohistochemical findings.
  • Surgery is the treatment of choice for ectopic meningioma and postoperative radiotherapy should be managed for patients with suspected invasive meningioma.
  • [MeSH-major] Mediastinal Neoplasms / radiography. Meningioma / radiography
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410481.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Wada K, Maruno M, Suzuki T, Kagawa N, Hashiba T, Fujimoto Y, Hashimoto N, Izumoto S, Yoshimine T: Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray. Neurol Res; 2005 Oct;27(7):747-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray.
  • BACKGROUND: Meningioma is the commonest brain tumor and many genetic abnormalities, such as the loss of chromosome 22q and the mutation of NF2, have been reported.
  • In this study, we used DNA microarray assay, which detects numerous genetic abnormalities simultaneously and analyses a global assessment of molecular events in meningioma cells.
  • We studied 31 meningiomas by GenoSensor Array 300 in order to detect the chromosomal aberrations and genetic abnormalities in the whole genome.
  • RESULTS: This study demonstrated not only classical chromosomal aberration, such as loss of chromosome 22q in 19 meningiomas (61.3%), but also new genetic characteristics of meningiomas, such as amplification of MSH2 in 16 meningiomas (51.6%), deletion of GSCL in 13 meningiomas (41.9%) and deletion of HIRA in seven meningiomas (22.6%).
  • CONCLUSIONS: These results suggest that DNA microarray assay is useful in research for the genetic characters of meningiomas and understanding tumorigenesis.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosome Mapping. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197812.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Sugo N, Yokota K, Kondo K, Harada N, Aoki Y, Miyazaki C, Nemoto M, Kano T, Ohishi H, Seiki Y: Early dynamic 201Tl SPECT in the evaluation of brain tumours. Nucl Med Commun; 2006 Feb;27(2):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In static SPECT, there was no significant difference between the STI of malignant tumours (glioblastoma and anaplastic astrocytoma) and that of benign tumours (low-grade glioma, meningioma, pituitary adenoma, neurinoma and haemangioblastoma) (3.7+/-1.5, 5.0+/-3.5, respectively).
  • On dynamic SPECT, DTI increased markedly over 15 min for malignant tumours.
  • The slope of the linear functions calculated from the DTRs was much higher in the malignant tumour group than in the benign tumour group (P<0.001).
  • CONCLUSIONS: We suggest that the performance of 201Tl dynamic SPECT for 15 min is useful for distinguishing malignant brain tumours from benign brain tumours and reduces the examination stress of patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404227.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium
  •  go-up   go-down


5. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J: Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol; 2010 May;97(3):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value.
  • Malignant gliomas--glioblastoma multiforme and anaplastic astrocytoma--are among the most fatal forms of cancer in humans.
  • We measured the HGF content of cerebrospinal fluid (CSF) from patients with malignant glioma glioblastoma multiforme (WHO IV; n = 14), anaplastic astrocytoma (WHO III; n = 4), and meningioma (WHO I; n = 9), and from control subjects (n = 25), and found a high concentration of HGF in patients with malignant glioma.
  • However, CSF concentrations from glioblastoma multiforme and anaplastic astrocytoma patients were not statistically significantly different (893 +/- 157 vs. 728 +/- 61, respectively; P > 0.01).
  • A negative correlation between HGF and survival was found at five years of follow-up (R = -0.922, R (2) = 0.850, P < 0.001).
  • Also, the HGF concentration in CSF was a reliable means of explaining the highly variable survival of patients with malignant glioma.
  • Our findings support the idea that measurement of HGF in CSF could be a useful tool for monitoring the biological activity of malignant glioma.
  • [MeSH-minor] Adult. Analysis of Variance. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):129-38 [15015778.001]
  • [Cites] Cancer Lett. 1998 Feb 27;124(2):149-55 [9500204.001]
  • [Cites] Int J Mol Med. 1999 May;3(5):531-6 [10202187.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 Mar 30;85(12):835-8 [15949402.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1077-82; discussion 1082-3 [10232541.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1721-9 [16452232.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3210-8 [12115353.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):143-9 [16648987.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9355-62 [16230398.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):517-30 [10571413.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):583-92 [16106403.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 [17062691.001]
  • [Cites] Front Biosci. 2004 Sep 01;9:3105-23 [15353341.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7443-8 [11416216.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4479-86 [15958633.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56 [10491431.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):82-8 [11296484.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] FASEB J. 2002 Jan;16(1):108-10 [11729097.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4578-85 [14555533.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):287-93 [10873600.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):743-7 [9207232.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):73-7 [9705834.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):139-50 [18234969.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1292-8 [16489086.001]
  • (PMID = 19856144.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


6. Okuducu AF, Zils U, Michaelis SA, Michaelides S, von Deimling A: Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology; 2006 Jun;48(7):836-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas.
  • AIMS: Matrix metalloproteinases (MMPs) are a pivotal enzyme system involved in extracellular matrix (ECM) degradation and are considered to be important in the development and invasion of human tumours.
  • Little is known about the regulation of MMPs in meningioma development and prognosis.
  • The aim of this study was to determine the relationship between the expression of Ets-1, MMP-2 and -9 and the malignant potential of meningiomas.
  • METHODS AND RESULTS: Seventy-four meningiomas of different histological grades were investigated immunohistochemically.
  • Up-regulation of Ets-1, MMP-2 and MMP-9 expression was observed in atypical and anaplastic meningiomas.
  • Invasive meningiomas showed increased immunohistochemical expression of these proteins compared with non-invasive meningiomas.
  • CONCLUSIONS: Ets-1 may be involved in the transcriptional regulation of MMP-2 and MMP-9 as well as in the invasive process in meningiomas.
  • Evaluation of these expressions might be of prognostic value for meningiomas.
  • [MeSH-major] Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology. Proto-Oncogene Protein c-ets-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Up-Regulation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722933.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Protein c-ets-1; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


7. Erman T, Hanta I, Haciyakupoğlu S, Zorludemir S, Zeren H, Göçer AI: Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature. J Neurooncol; 2005 Sep;74(2):179-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature.
  • A case of recurrent meningioma with atypical features and extracranial metastases is reported.
  • A 34-year-old female was operated in 1996, 2000, and 2002, and frontal parasagittal meningioma was extirpated.
  • Histological diagnoses of all the resected tumors were meningotheliomatous meningioma, WHO Grade I.
  • However, 2 years later, the tumor recurred in the frontal scalp and was removed again totally.
  • Histological diagnosis was reported as an atypical meningioma; meningotheliomatous type; WHO Grade II.
  • Cytopathology was consistent with malignant meningioma, metastasis from the patient's known intracranial meningioma.
  • We reviewed and discussed the histopathological features and mechanisms of metastasizing meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 1995 Aug;45(8):617-21 [7496509.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8 [8955436.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Diagn Cytopathol. 1999 May;20(5):291-4 [10319230.001]
  • [Cites] J Clin Neurosci. 2000 Jan;7(1):69-72 [10847658.001]
  • [Cites] Br J Radiol. 1999 May;72(857):513-6 [10505022.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1144-50 [8214259.001]
  • [Cites] Acta Neurol Scand. 2000 Sep;102(3):200-2 [10987382.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Clin Nucl Med. 2002 Oct;27(10 ):701-4 [12352110.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Mayo Clin Proc. 1999 Nov;74(11):1129-33 [10560602.001]
  • [Cites] Surg Today. 1998;28(9):953-8 [9744408.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Mar;21(3):553-5 [11888783.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 16193389.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Pfister C, Ritz R, Endemann E, Schittenhelm J, Bornemann A, Tatagiba MS, Roser F: Evidence of ubiquitous in vivo and in vitro expression of pro-apoptotic Smac/DIABLO protein in meningioma cell lines. Oncol Rep; 2009 May;21(5):1181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of ubiquitous in vivo and in vitro expression of pro-apoptotic Smac/DIABLO protein in meningioma cell lines.
  • Although meningiomas are one of the most common tumors in the central nervous system, the adjuvant treatment for recurrent or malignant meningiomas is not satisfactory.
  • As Smac/DIABLO has not been previously analyzed in meningiomas, We investigated the expression of Smac/DIABLO and survivin in primary meningioma cultures in vivo and in vitro.
  • Expression of Smac/DIABLO, survivin and single-stranded (ss)DNA in vivo were determined immunohistochemically in 100 meningioma surgical specimens, dura and normal human cortex.
  • The expression of the apoptotic enzymes in vitro was analyzed after RNA and protein isolation of all meningiomas via Western blotting and PCR.
  • All examined meningiomas and normal cerebral cortex displayed intense positive cytoplasmic Smac/DIABLO immunoreactivity.
  • PCR analysis displayed no changes of Smac/DIABLO and survivin expression in different meningioma grades, normal human cortical cortex or dura.
  • Constant high-level Smac/DIABLO respectively low-level survivin expression in meningiomas and normal brain demonstrate similar apoptotic behavior of meningiomas compared to normal brain tissue.
  • These findings indicate no pathological overexpression of survivin in meningiomas as is evident in several other cancer types impeding apoptosis.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Mitochondrial Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / genetics. Male. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360292.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


9. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature.
  • In extremely rare condition, meningioma may occur together with meningioangiomatosis, and only 19 cases have been described in English literature until now.
  • We now report a case of meningioangiomatosis-associated meningioma with atypical and clear cell variant.
  • A 34-year-old man presented a 3-month history of progressive numbness and weakness of his left lower extremity.
  • Microscopically, parts of lesions were atypical and clear cell meningioma corresponding to WHO grade II.
  • Neoplastic cells in atypical meningioma area were immunoreactive to epithelial membrane antigen (EMA) with high MIB-1 index of up to 20%.
  • The diagnosis of atypical meningioma associated with sporadic meningioangiomatosis was made.
  • To our knowledge, this is the first case of a meningioangiomatosis-associated meningioma with atypical and clear cell variant component to be described.
  • Meningioangiomatosis-associated meningioma is more likely to occur in younger patients and histologically to mimic parenchymal invasion of brain.
  • We suggest that postoperative radiotherapy or chemotherapy should be given careful consideration to avoid over-treatment due to erroneously interpret as malignant meningioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


10. Katz TS, Amdur RJ, Yachnis AT, Mendenhall WM, Morris CG: Pushing the limits of radiotherapy for atypical and malignant meningioma. Am J Clin Oncol; 2005 Feb;28(1):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pushing the limits of radiotherapy for atypical and malignant meningioma.
  • PURPOSE: The purpose of this study was to report the outcome of an extremely aggressive radiotherapy program in patients with atypical and malignant meningioma (60 Gy at 1.5 Gy per fraction twice daily +/- radiosurgery boost).
  • METHODS AND MATERIALS: Thirty-six patients received radiotherapy with curative intent between 1984 and 1999 for atypical (27 patients) or malignant (9 patients) meningioma.
  • All patients had a minimum of 2 years follow up.
  • RESULTS: The overall 5-year local control, cause-specific survival, and absolute survival rates were 45%, 39%, and 36%, respectively.
  • CONCLUSION: Our data suggests that 50 to 60 Gy delivered with conventional, once-daily fractionation is probably the optimal schedule for atypical and malignant meningioma.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Humans. Male. Middle Aged. Radiosurgery. Survival Rate

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685038.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Chen F, Zhang S: Diagnosis and treatment of the primary malignant meningioma in mediastinum: a case report. South Med J; 2009 Nov;102(11):1164-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of the primary malignant meningioma in mediastinum: a case report.
  • Primary ectopic meningioma is rare and usually limited to the head and neck region.
  • Until now its occurrence in the mediastinum has not been reported in the literature searched on Medline using the keywords meningioma and mediastinum.
  • We report here a case of primary mediastinal malignant meningioma which was treated by surgical resection and additionally followed by radiotherapy.
  • The clinical features, treatment, pathological findings, and prognosis are analyzed and the literature based on ectopic meningioma is reviewed.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Prognosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19864997.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 6
  •  go-up   go-down


12. Qi ZG, Li YX, Wang Y, Geng DY, Li KC, Shen TZ, Chen XR: Lipid signal in evaluation of intracranial meningiomas. Chin Med J (Engl); 2008 Dec 5;121(23):2415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid signal in evaluation of intracranial meningiomas.
  • BACKGROUND: Using magnetic resonance imaging, diagnosis of malignant meningioma from benign meningioma with atypical features is uncertain.
  • We evaluated the value of lipid signal in differentiating intracranial meningiomas.
  • RESULTS: Twenty-nine meningiomas were histologically benign (eleven meningothelial, thirteen fibrous, four transitional and one microcystic), three were atypical, and two were anaplastic.
  • Lipid signal was detected in ten cases: two anaplastic, three atypical, two fibrous and three meningothelial meningiomas.
  • With creatinine peak in the normal white matter chosen as internal standard, lipid/creatinine ratios of anaplastic, atypical and benign meningiomas were 0.844 +/- 0.027 (range from 0.725 to 0.994), 0.465 +/- 0.023 (range from 0.239 to 0.724), and 0.373 +/- 0.016 (range from 0.172 to 0.571) respectively.
  • Highly significant differences were noted between anaplastic and the other two subtypes.
  • Patchy necrosis was observed in anaplastic meningioma, while focal necrosis was noted in atypical meningioma with HE stain.
  • KP-1 stain demonstrated histocytes containing lipids in the necrotic region of anaplastic and atypical meningioma.
  • CONCLUSION: The lipid signal at 1.3 ppm is a useful marker in evaluating the malignancy of intracranial meningiomas, especially in the differential diagnosis of anaplastic meningioma.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102960.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • OBJECT: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult


14. Boskos C, Feuvret L, Noel G, Habrand JL, Pommier P, Alapetite C, Mammar H, Ferrand R, Boisserie G, Mazeron JJ: Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):399-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma.
  • PURPOSE: To evaluate retrospectively the efficacy of conformal fractionated radiotherapy combining proton and photon beams after primary surgery for treatment of atypical and malignant meningiomas.
  • PATIENTS AND METHODS: Between September 1999 and October 2006, 24 patients (12 male, 12 female) with histopathologically proven meningioma (atypical 19, malignant 5) received postoperative combined radiotherapy with a 201-MeV proton beam at the Centre Protontherapie d'Orsay and a high-energy photon beam.
  • Median gross tumor volume and clinical target volume were 44.7 cm(3) and 153.3 cm(3), respectively.
  • The overall mean local relapse-free interval was 27.2 (10-50) months, 28.3 (10-50) months for atypical meningioma and 23 (13-33) months for malignant meningioma.
  • One-, 2-, 3-, 4-, 5-, and 8- year local control rates for the entire group of patients were 82.9% +/- 7.8%, 82.9% +/- 7.8%, 61.3% +/- 11%, 61.3% +/- 11%, 46.7% +/- 12.3%, and 46.7% +/- 12.3%, respectively.
  • One-, 2-, 3-, 4-, 5-, and 8- year overall survival rates were 100%, 95.5% +/- 4.4%, 80.4% +/- 8.8%, 65.3% +/- 10.6%, 53.2% +/- 11.6%, and 42.6% +/- 13%, respectively.
  • CONCLUSIONS: Postoperative combination of conformal radiotherapy with protons and photons for atypical and malignant meningiomas is a well-tolerated treatment producing long-term tumor stabilization.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Photons / therapeutic use. Protons / therapeutic use. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, High-Energy / methods. Retrospective Studies. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203844.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


15. Kunishio K, Kobayashi K, Kagawa M, Makabe T, Matsumoto A, Matsumoto Y: [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene]. Gan To Kagaku Ryoho; 2007 Feb;34(2):265-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].
  • We report a case with malignant meningioma in which new preliminary treatment trial was performed by chemotherapy using anti-cancer drugs selected on the basis of multidrug resistance gene mRNA expression, such as MDR1, MGMT, MRP1, MRP2, MXR1, and DNA topoisomerase II alpha, from RT-PCR assay.
  • A 43-year-old female had been operated for parasagittal anaplastic meningioma three times because of recurrences. partial removal of tumor was performed at the 3rd operation.
  • The patient was given mitoxantrone and hydroxyurea following irradiation, after which the tumor did not recur for three years.
  • Preliminary individual adjuvant chemotherapy based on mRNA expression of drug-resistance gene is available for the treatment of recurrent malignant meningioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. DNA Modification Methylases. DNA Repair Enzymes. Drug Administration Schedule. Female. Humans. Hydroxyurea / administration & dosage. Membrane Transport Proteins / biosynthesis. Mitoxantrone / administration & dosage. Multidrug Resistance-Associated Proteins / biosynthesis. P-Glycoprotein / biosynthesis. P-Glycoprotein / genetics. RNA, Messenger / biosynthesis. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301541.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / multidrug resistance-associated protein 2; BZ114NVM5P / Mitoxantrone; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


16. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res; 2005 Apr;163(4):424-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aims were to assess the risk of radiation-induced malignant brain tumors and benign meningiomas after childhood exposure and to investigate the role of potential modifiers of that risk.
  • After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively.
  • The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas.
  • The ERR for both types of tumor remains elevated at 30-plus years after exposure.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Causality. Child. Child, Preschool. Cohort Studies. Comorbidity. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Incidence. Infant. Israel / epidemiology. Longitudinal Studies. Male. Middle Aged. Radiation Dosage. Risk Factors. Sex Distribution


17. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A: Molecular signatures define two main classes of meningiomas. Mol Cancer; 2007;6:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures define two main classes of meningiomas.
  • BACKGROUND: Meningiomas are common brain tumors that are classified into three World Health Organization grades (benign, atypical and malignant) and are molecularly ill-defined tumors.
  • The purpose of this study was identify molecular signatures unique to the different grades of meningiomas and to unravel underlying molecular mechanisms driving meningioma tumorigenesis.
  • RESULTS: We have used a combination of gene expression microarrays and array comparative genomic hybridization (aCGH) to show that meningiomas of all three grades fall into two main molecular groups designated 'low-proliferative' and 'high-proliferative' meningiomas.
  • While all benign meningiomas fall into the low-proliferative group and all malignant meningiomas fall into the high-proliferative group, atypical meningiomas distribute into either one of these groups.
  • High-proliferative atypical meningiomas had an elevated median MIB-1 labeling index and a greater frequency of copy number aberrations (CNAs) compared to low-proliferative atypical meningiomas.
  • Additionally, losses on chromosome 6q, 9p, 13 and 14 were found exclusively in the high-proliferative meningiomas.
  • We have identified genes that distinguish benign low-proliferative meningiomas from malignant high-proliferative meningiomas and have found that gain of cell-proliferation markers and loss of components of the transforming growth factor-beta signaling pathway were the major molecular mechanisms that distinguish these two groups.
  • CONCLUSION: Collectively, our data suggests that atypical meningiomas are not a molecularly distinct group but are similar to either benign or malignant meningiomas.
  • It is anticipated that identified molecular and CNA markers will potentially be more accurate prognostic markers of meningiomas.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / classification. Meningeal Neoplasms / genetics. Meningioma / classification. Meningioma / genetics. Nucleic Acid Hybridization / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Deletion. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):149-58 [11859969.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):445-54 [16772868.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2907-18 [15837741.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Lab Invest. 1992 Sep;67(3):360-8 [1328762.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):633-42 [1325741.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):148-58 [12712009.001]
  • [Cites] Genome Biol. 2003;4(1):R7 [12540299.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Genome Res. 2002 Feb;12(2):325-32 [11827952.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 17937814.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2173907
  •  go-up   go-down


18. van der Meij JJ, Boomars KA, van den Bosch JM, van Boven WJ, de Bruin PC, Seldenrijk CA: Primary pulmonary malignant meningioma. Ann Thorac Surg; 2005 Oct;80(4):1523-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary malignant meningioma.
  • Primary pulmonary meningiomas are relatively rare and mostly benign.
  • To exclude pulmonary metastasis of an intracranial meningioma, imaging studies of the brain should be performed.
  • We believe that only one primary pulmonary malignant meningioma in which a metastasis from the brain was excluded has been reported.
  • In this report we describe a second case with malignant features.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Neoplasm Invasiveness. Pleural Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181912.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Ahmadi SA, Samadi N: Evaluation of argyrophilic nucleolar organizer region staining in predicting the behavior of meningiomas. Ann Saudi Med; 2006 Jan-Feb;26(1):38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of argyrophilic nucleolar organizer region staining in predicting the behavior of meningiomas.
  • Comparing nonrecurrent, recurrent, atypical and malignant meningiomas we studied the value of the routine applicability of the AgNOR count in the prognostication of this tumor.
  • PATIENTS AND METHODS: Two hundred and thirty-eight meningiomas were reviewed blindly and graded using WHO grading schema.
  • Eighty-one cases were selected and arranged in six groups according to clinical data and grading: 14 benign non-recurrent meningiomas; 14 primary benign recurrent meningiomas and their subsequent benign recurrences; 14 atypical; 11 malignant and 14 spinal meningiomas.
  • There was a significant difference between benign non-recurrenttumors versus benign recurrent (P<0.0001) and atypical or malignant (P<0.0001) tumors.
  • A difference was also noted between the recurring tumors versus malignant ones (P = 0.002) but no significant difference was seen between recurrent and atypical; atypical and malignant; intracranial and intraspinal; and primary of recurring meningiomas with their subsequent recurrences.
  • A mean AgNOR count of <2.3 could separate benign tumors from atypical or malignant meningiomas with 93% specificity; and 93% of tumors with benign histology had no recurrence potential if their mean AgNOR count was less than 1.8.
  • CONCLUSION: This study indicates that in meningioma, the AgNOR count has a good correlation with tumor grading and recurrence, which may aid pathologists and clinicians in predicting tumor behavior.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Nucleolus Organizer Region / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Coloring Agents. Female. Humans. Male. Middle Aged. ROC Curve

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521873.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


20. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • INTRODUCTION: One in every thousand intracranial meningiomas metastatize extracranially.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • No postoperative complications ocurred and he is, so far, free from primary and secondary disease.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • The interval between the onset of the intracranial disease and the appearance of the metastasis varies from months to many years.
  • The value of transpedicular biopsy is widely recognized (efficacy over 80%) and the suitability of the specimen for pathological examination improves when wide inner caliber trephines are used.
  • We believe this case represents a paradigmatic indication of this technique because it respects the concepts of radical resection and spinal stability, and offers an opportunity for the curation of the disease.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH: Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution.
  • PURPOSE: To evaluate the outcomes for patients with Grade III meningiomas as defined by the 2007 World Health Organization standards.
  • METHODS AND MATERIALS: The slides from patients who had been treated at the Cleveland Clinic for malignant meningiomas were reviewed by a single neuropathologist.
  • The data from 13 patients treated between 1984 and 2006 satisfied the World Health Organization 2007 definition of Grade III meningioma.
  • RESULTS: From the primary surgery, the median survival was 3.4 years, the 5-year survival rate was 47.2%, and the 8-year survival rate was 12.2%.
  • CONCLUSION: This is one of the few studies reporting the outcomes for malignant meningioma patients according to recent definitions.
  • Our results are consistent with existing reports of the overall poor outcomes for atypical and malignant meningioma patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy. Postoperative Complications. Radiosurgery. Radiotherapy / adverse effects. Radiotherapy Dosage. Survival Rate. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427553.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Terzi A, Saglam EA, Barak A, Soylemezoglu F: The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract; 2008;204(5):305-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
  • Although histologic grading of meningiomas has prognostic and clinical implications, it is difficult in some cases to predict the outcome of patients.
  • There have been several efforts to evaluate the use of different immunohistochemical markers for predicting meningioma prognosis.
  • We analyzed the immunohistochemical expression of Ki-67, p53, p21, p16, and PTEN proteins in 130 meningiomas (64 benign, 39 atypical, and 27 malignant meningiomas) using tissue microarray.
  • There was a statistically significant correlation between the expression of Ki-67, p53, p21, p16, and the grade of meningiomas (p0.001).
  • In contrast, multivariate analysis revealed that only tumor grade is an independent factor for predicting meningioma recurrence.
  • We conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas, especially in histological borderline cases.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Immunohistochemistry. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningioma / chemistry. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Logistic Models. Male. Middle Aged. Neoplasm Staging. Neurofibromatosis 2 / immunology. Neurofibromatosis 2 / metabolism. PTEN Phosphohydrolase / analysis. Recurrence. Risk Assessment. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374497.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


23. Hasegawa T, Kida Y, Yoshimoto M, Koike J, Iizuka H, Ishii D: Long-term outcomes of Gamma Knife surgery for cavernous sinus meningioma. J Neurosurg; 2007 Oct;107(4):745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of Gamma Knife surgery for cavernous sinus meningioma.
  • OBJECT: The aim of this study was to evaluate long-term outcomes, including tumor control and neurological function, in patients with cavernous sinus meningiomas treated using Gamma Knife surgery (GKS).
  • METHODS: One hundred fifteen patients with cavernous sinus meningiomas, excluding atypical or malignant meningiomas, were treated with GKS between 1991 and 2003.
  • RESULTS: The actuarial 5- and 10-year progression-free survival rates were 87 and 73%, respectively.
  • Similarly, the actuarial 5- and 10-year focal tumor control rates were 94 and 92%, respectively.
  • CONCLUSIONS: Gamma Knife surgery is a safe and effective treatment over the long term in selected patients with cavernous sinus meningiomas.
  • [MeSH-major] Cavernous Sinus / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Morbidity. Prognosis. Radiation Dosage. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17937218.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. García-Purriños FJ, Rosell Cervilla A, Lemberg P, Calvo Moya J: [Nasal malignant meningioma]. Acta Otorrinolaringol Esp; 2005 Oct;56(8):373-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal malignant meningioma].
  • [Transliterated title] Meningioma maligno nasal. manejo de un caso y revisión de la literatura.
  • Extracraneal meningiomas represent 2% of all meningiomas and can appear in different locations including paranasales sinuses.
  • There are no statistics regarding ectopic malignant meningiomas, but they are considered extremely rare.
  • We present a patient with a malignant meningioma of the etmoidal sinus, his treatment and the evolution over a five year period.
  • [MeSH-major] Meningioma / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285437.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


25. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol; 2005 Apr;36(4):416-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas.
  • Hypermethylation of promoter CpG islands is a common epigenetic event in a variety of human cancers.
  • The aim of this study was to investigate whether promoter hypermethylation of cancer-related genes is involved in the development and progression of meningiomas.
  • The methylation status at the promoter region of 10 cancer-related genes was examined by methylation-specific polymerase chain reaction in a cohort of 48 meningiomas including 16 benign, 19 atypical, and 13 anaplastic variants.
  • Our results showed that 50% (24/48) of meningiomas exhibited promoter hypermethylation in at least one of the genes but not in normal leptomeninges, indicating that aberrant hypermethylation is tumor-specific.
  • Treatment of IOMM-Lee meningioma cell line with 5-aza-2'-deoxycytidine restored expression of O 6 -methylguanine-DNA methyltransferase and death-associated protein kinase 1, providing evidence that promoter hypermethylation contributes to transcriptional silencing.
  • The frequencies of methylation of any single gene in benign, atypical, and malignant meningiomas were 6% (1/16), 74% (14/19), and 69% (9/13), respectively.
  • Of 48 tumors, 13 (27%) showed that concurrent hypermethylation of two or more genes studied were of atypical or anaplastic type.
  • Statistical analysis revealed that the incidence of promoter hypermethylation of any single gene, of multiple genes, or of glutathione S -transferase P1 was significantly associated with atypical and anaplastic meningiomas ( P < .0001, P = .004, and P = .004, respectively).
  • In conclusion, this study demonstrates that aberrant hypermethylation profile is associated with atypical and anaplastic meningiomas, suggesting that epigenetic change may be involved in malignant progression of meningiomas.
  • [MeSH-major] Azacitidine / analogs & derivatives. CpG Islands. DNA Methylation. Meningioma / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892004.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


26. Garcia-Conde M, Roldan-Delgado H, Martel-Barth-Hansen D, Manzano-Sanz C: Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report. Neurocirugia (Astur); 2009 Dec;20(6):541-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report.
  • OBJECTIVE: Malignant intraventricular meningiomas are very rare.
  • We present herein the first case of a malignant intraventricular meningioma with extraneural metastases.
  • CLINICAL PRESENTATION: We report a 44 year-old-man with a history of progressive headache and disorientation.
  • Histological examination demonstrated an atypical meningioma.
  • Histological examination showed anaplastic meningioma.
  • Biopsy was consistent with liver metastases of a malignant meningioma.
  • The patient died of acute liver failure seven months after initial diagnosis.
  • CONCLUSION: Malignant intraventricular meningiomas are prone to recur and develop metastases, mainly through the CSF.
  • Therefore, when systemic deterioration occurs in a patient with a malignant intraventricular meningioma, metastases to extraneural organs such as the liver must be ruled out.
  • [MeSH-major] Anaplasia / pathology. Liver Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967319.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Liu Y, Liu M, Li F, Wu C, Zhu S: Malignant meningiomas: a retrospective study of 22 cases. Bull Cancer; 2007 Oct;94(10):E27-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningiomas: a retrospective study of 22 cases.
  • Malignant (anaplastic) meningioma constitutes a rare subset of meningioma.
  • The aim of the study was to study clinical features and management of malignant meningiomas.
  • Twenty-two patients with malignant meningiomas were surgically treated in our department between January 1986 and January 2005 in Qilu hospital, and we reviewed each patient's clinical records, radiological findings, operative reports, and pathological examinations.
  • The follow-up period ranged from six months to ten years.
  • Overall 5-year survival and recurrence-free survival estimates were 36.4 and 27.3%, respectively.
  • Surgical resection and adjuvant radiotherapy are the main treatments for malignant meningiomas, and the degree of tumor removal is the leading factor determining postoperative recurrence and survival.
  • [MeSH-major] Meningeal Neoplasms. Meningioma
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964977.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S: Genomic landscape of meningiomas. Brain Pathol; 2010 Jul;20(4):751-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic landscape of meningiomas.
  • Meningiomas are one of the most common adult brain tumors.
  • Currently, the molecular determinants predicting recurrence and malignant transformation are lacking.
  • We performed retrospective global genetic and genomic analysis of 85 meningioma samples of various grades.
  • In addition to chromosome 22q loss, which was detected in the majority of clinical samples, chromosome 6q and 14q loss was significantly more common in recurrent tumors and was associated with anaplastic histology.
  • Five "classes" of meningiomas were detected by gene expression analysis that correlated with copy number alterations, recurrent status and malignant histology.
  • These classes more accurately identified recurrent tumors relative to Ki-67 index and extent of surgical resection, and highlight substantial expression heterogeneity between meningiomas.
  • These data offer the most complete description of the genomic landscape of meningiomas, and provide broad genomic information that may be used to further stratify meningioma patients into prognostic risk groups.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):5057-60 [16124066.001]
  • [Cites] Am J Hum Genet. 2005 Nov;77(5):709-26 [16252233.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E9 [16398473.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] DNA Res. 2007 Feb 28;14(1):1-11 [17363414.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):21962-72 [17545167.001]
  • [Cites] Genomics. 1996 Aug 15;36(1):112-7 [8812422.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] Genome Biol. 2007;8(6):R112 [17570842.001]
  • [Cites] Childs Nerv Syst. 2008 Jul;24(7):855-7 [18236049.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603 [9892679.001]
  • [Cites] Hum Mol Genet. 2000 Jun 12;9(10):1495-500 [10888600.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):317-22 [11901424.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):55-63; discussion 63-4 [14683541.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1014-20 [14749765.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12734-43 [14718544.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1087-92 [15492797.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [ErratumIn] Brain Pathol. 2011 Jul;21(4):478
  • (PMID = 20015288.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052108-05; United States / NINDS NIH HHS / NS / U24 NS052108; United States / NINDS NIH HHS / NS / U24 NS052108-05; United States / NINDS NIH HHS / NS / U24NS052108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS161003; NLM/ PMC3167483
  •  go-up   go-down


29. Bollag RJ, Vender JR, Sharma S: Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence. Neuropathology; 2010 Jun;30(3):279-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.
  • The current WHO 2007 classification divides meningiomas into a 3-grade prognostic hierarchy.
  • Recent literature evokes two pathways to disease progression in meningiomas akin to a comparable paradigm in gliomas, but without similar prognostic connotation: de novo anaplastic meningioma (better prognosis), and transformed meningioma (worse prognosis).
  • We present two adult cases of transformed meningiomas that display a spectrum of morphologic progression.
  • Case 1 at presentation showed a random admixture of meningothelial, atypical and anaplastic meningioma.
  • The tumor recurred as anaplastic meningioma.
  • Case 2 presented as a chordoid meningioma, but recurred as anaplastic meningioma mainly at the invasive front in transition with residual chordoid pattern.
  • In accordance with the dire prognosis for anaplastic meningioma, both patients succumbed to their disease within 2 months of recurrence.
  • The present study highlights two main points: First, that proper recognition of focal high-grade areas in a heterogeneous low-grade meningioma (case 1) provides critical morphologic clues to spatial histologic progression and predicts aggressive biologic behavior, as evidenced by progression to frankly anaplastic meningioma at recurrence.
  • Second, the presence of papillary in addition to anaplastic areas, in the recurrence of a previously diagnosed chordoid meningioma supports the ostensibly heightened transforming potential of grade II meningiomas, but also reflects on the morphologic heterogeneity of high-grade meningiomas, and their potentially diverse pathways of progression.
  • We propose that grading of meningiomas as outlined by WHO is of more critical prognostic import than histologic sub-typing, and must include a thorough survey of the tumor-brain interface.
  • Future molecular genetic correlates, akin to those characterized in gliomas, could help stratify prognostic subcategories to refine meningioma grading, and govern optimal therapeutic strategies.
  • [MeSH-major] Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / pathology. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780983.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


30. Hope AJ, Mansur DB, Tu PH, Simpson JR: Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma. Childs Nerv Syst; 2006 Sep;22(9):1201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.
  • INTRODUCTION: Malignant brain tumors have been reported to occur after childhood irradiation more frequently than in the nonirradiated population.
  • DISCUSSION: In this study, we report the case of a 15-year-old boy treated for medulloblastoma with surgery and craniospinal radiotherapy, who developed a meningioma 18 years after initial treatment and subsequently an anaplastic astrocytoma 23 years after primary treatment.
  • The meningioma was resected without complications.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):469-74 [2536806.001]
  • [Cites] Ann Neurol. 1978 Oct;4(4):319-21 [727737.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] Childs Nerv Syst. 2004 Apr;20(4):243-6 [14704813.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Lancet. 1997 May 10;349(9062):1369 [9149706.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Jan;16(1):97-101 [12585346.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Clin Neuropathol. 1994 Sep-Oct;13(5):281-5 [7805312.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):622-7 [632887.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(7):697-700 [11534690.001]
  • [Cites] J Neuroradiol. 1983;10 (1):43-9 [6864263.001]
  • [Cites] Neurology. 1981 May;31(5):616-9 [7194977.001]
  • [Cites] Neurosurgery. 1980 May;6(5):546-51 [6251397.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Mar;100(1):56-9 [9637208.001]
  • [Cites] Can J Neurol Sci. 1984 Nov;11(4):475-8 [6518432.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]
  • [Cites] Eur J Paediatr Neurol. 1999;3(4):177-80 [10476368.001]
  • [Cites] Can J Neurol Sci. 1992 Nov;19(4):498-503 [1330262.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):445-9 [682008.001]
  • [Cites] Am J Public Health Nations Health. 1966 Dec;56(12):2114-20 [5334312.001]
  • [Cites] Cancer. 1979 Jan;43(1):129-36 [104784.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]
  • (PMID = 16570196.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


31. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A: Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology; 2007 Apr;27(2):114-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
  • Meningiomas represent the second most common central nervous system neoplasms in adults and account for 26% of all primary brain tumors.
  • Although most are benign, between 5% and 15% of meningiomas are atypical (grade II) whereas 1-2% are anaplastic meningiomas (grade III).
  • Although histological grade is the most relevant prognostic factor, there are some unusual cases in which establishing a diagnosis of high-grade meningioma following 2000 World Health Organization (WHO) histological criteria is extremely difficult.
  • Therefore, the aim of the present study was to evaluate the predictive value of Ki-67 labeling index and its contribution to current WHO classification in predicting tumor recurrence and overall survival in patients with high-grade meningiomas.
  • A total of 28 patients (with 16 atypical meningiomas and 12 anaplastic meningiomas) were evaluated for demographic, clinical, radiological and therapeutic variables, and for Ki-67 immunohistochemistry.
  • More importantly, this predictive value was maintained in both patients with atypical and patients with anaplastic meningioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neuropathology. 2008 Feb;28(1):106-7 [18181839.001]
  • (PMID = 17494511.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


32. Tong-tong W, Li-juan B, Zhi L, Yang L, Bo-ning L, Quan H: Clear cell meningioma with anaplastic features: case report and review of literature. Pathol Res Pract; 2010 May 15;206(5):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma with anaplastic features: case report and review of literature.
  • Clear cell meningioma (CCM) is an uncommon variant of meningioma, corresponding to WHO grade II.
  • We present two cases of CCMs with anaplastic features in the intracranial and intraspinal region.
  • The first case is a 65-year-old male who gradually developed changes in behavior over a period of 1 year.
  • The second case is a 35-year-old female who presented with a 7-month history of posterior cervicothoracic pain and dysuria for 1 week.
  • On histological examination, both tumors partly exhibited unusual anaplastic appearances with nuclear pleomorphism, high mitotic activity and necrosis, distinct from classical CCMs.
  • A diagnosis of CCM with anaplastic features was made (WHO grade III).
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Anaplasia / pathology. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19857933.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Petrovic NS, Grujicic D, Artiko VM, Sobic-Saranovic DP, Gajic MM, Jaksic E, Grajic MM, Antonovic OJ, Petrovic MN, Obradovic VB: Investigation of blood perfusion and metabolic activity of brain tumours in adults by using 99mTc-methoxyisobutylisonitrile. Nucl Med Commun; 2010 Nov;31(11):962-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of blood perfusion and metabolic activity of brain tumours in adults by using 99mTc-methoxyisobutylisonitrile.
  • OBJECTIVES: (i) To examine blood perfusion and metabolic activity of various brain tumours using radionuclide cerebral angiography (RCA) and single-photon emission tomography (SPET) after a single dose of Tc-methoxyisobutylisonitrile (MIBI). (ii) To examine if the inclusion of RCA can improve insight into the relative contribution of tumour perfusion to the uptake of MIBI shown by SPET, and to improve evaluation of tumour biology. (iii) To determine the value and the roles of MIBI in the management of brain tumour patients.
  • METHODS: Fifty adult patients (38 male, 12 female) with a total of 56 intracranial space-occupying lesions have been included prospectively, 37 of which were newly diagnosed and the remaining with signs of recurrence/rest of earlier resected and irradiated brain tumours.
  • The control group consisted of nine volunteers with no evidence of organic cerebral disease.
  • Scintigraphic examination consisted of a dynamic first-pass study lasting 60 s (3 s/frame) and two SPET studies (60 projections each, 25 s/projection), starting 15 min and 2 h after intravenous injection of MIBI.
  • RESULTS: Mean P of various brain tumours (low-grade gliomas 0.98, anaplastic gliomas 1.14, glioblastoma multiforme 1.20, metastases 1.09, lymphomas 1.08) differ little from each other and do not exceed maximal physiologic regional variations of cerebral perfusion (1.33), with the exception of meningioma (1.87, F=2.83, P=0.015).
  • The receiver operating characteristics curve analysis of P showed that for the cut-off value of 1.45 the sensitivity for distinguishing meningioma from other tumours is 75%, specificity 87%, positive predictive value 33% and negative predictive value 97%.
  • Mean E of malignant brain tumours (8.3, n=31, 23 primary, eight secondary), except anaplastic gliomas (3.5, n=5), differed significantly (P=0.02) from those of benign gliomas (3, n=9) but not from that of meningioma (11.9, n=4).
  • The cut-off value for distinguishing malignant from benign lesions on the basis of E set at 4.8 resulted in sensitivity 67%, specificity 75%, accuracy 70%, positive predictive value 80% and negative predictive value 60%.
  • D and R showed tendency of wash-out of MIBI from meningiomas, but otherwise did not improve the results substantially.
  • If the perfusion index is less than 1.45, then meningioma can be ruled out.
  • [MeSH-minor] Adolescent. Adult. Aged. Biological Transport. Female. Follow-Up Studies. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802363.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


34. Giussani C, Pirillo D, Roux FE: Mirror of the soul: a cortical stimulation study on recognition of facial emotions. J Neurosurg; 2010 Mar;112(3):520-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: After a preoperative neuropsychological evaluation, 18 consecutive patients with right hemispheric lesions (5 metastases, 6 high-grade gliomas, 4 low-grade gliomas, 2 arteriovenous malformations, and 1 malignant meningioma) were tested by intraoperative cortical stimulation while performing a facial emotion recognition task along with sensorimotor and visuospatial tasks.
  • CONCLUSIONS: The finding of interference sites in facial emotion recognition in the right posterior perisylvian area, independent to sensorimotor or visuospatial orientation processes, reinforces the theory about the role of anatomically and functionally segregated right hemisphere structures in this cognitive process.
  • [MeSH-minor] Adult. Aged. Brain Mapping / methods. Brain Neoplasms / physiopathology. Brain Neoplasms / surgery. Electric Stimulation / methods. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Neurosurgical Procedures. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538049.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Tufan K, Dogulu F, Kurt G, Emmez H, Ceviker N, Baykaner MK: Intracranial meningiomas of childhood and adolescence. Pediatr Neurosurg; 2005 Jan-Feb;41(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas of childhood and adolescence.
  • Meningiomas are rare intracranial neoplasms in childhood and adolescence, representing 0.4-4.1% of the pediatric-age tumors and 1.5-1.8% of all intracranial meningiomas.
  • The goal of this study was to determine epidemiology, clinical and radiological features, and long-term outcome of childhood and adolescence meningiomas.
  • Patients operated for intracranial meningiomas of childhood and adolescence between 1983 and 2003 at Gazi University School of Medicine, Department of Neurosurgery, were evaluated retrospectively.
  • This study presents 11 cases (6 male, 5 female), ranging in age from 14 months to 17 years.
  • Age and sex distribution, presenting symptoms, neurological examination results, location of meningiomas, radiological and histopathological findings, and prognosis were reviewed.
  • Atypical and malignant meningiomas seem to be more common in childhood and adolescence with respect to adult meningiomas.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15886506.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


36. Zada G, Pagnini PG, Yu C, Erickson KT, Hirschbein J, Zelman V, Apuzzo ML: Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas. Neurosurgery; 2010 Aug;67(2):322-8; discussion 328-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas.
  • OBJECT: To characterize the timing and patterns of long-term treatment failure after Gamma Knife radiosurgery (GKRS) for benign meningiomas.
  • METHODS: Data were retrospectively reviewed in 116 patients who underwent 136 GKRS treatments for benign intracranial meningiomas from 1996 to 2004.
  • Patients with atypical or malignant meningiomas were excluded.
  • Seven patients experienced disease progression in 8 tumors, occurring at a mean time of 90 months.
  • The overall 5-year and 10-year actuarial tumor control rate was 98.9% and 84%, respectively.
  • CONCLUSIONS: GKRS demonstrates excellent long-term tumor control in the management of benign meningiomas.
  • Tumor progression occurred at a mean time of 7.5 years after GKRS, reinforcing the need for long-term surveillance despite initial tumor control.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Failure. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644417.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Mattozo CA, De Salles AA, Klement IA, Gorgulho A, McArthur D, Ford JM, Agazaryan N, Kelly DF, Selch MT: Stereotactic radiation treatment for recurrent nonbenign meningiomas. J Neurosurg; 2007 May;106(5):846-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for recurrent nonbenign meningiomas.
  • OBJECT: The authors analyzed the results of stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) for the treatment of recurrent meningiomas that were described at initial resection as showing aggressive, atypical, or malignant features (nonbenign).
  • METHODS: Twenty-five patients who underwent SRS and/or SRT for nonbenign meningiomas between December 1992 and August 2004 were included.
  • All histological sections were reviewed and reclassified according to World Health Organization (WHO) 2000 guidelines as benign (Grade I), atypical (Grade II), or anaplastic (Grade III) meningiomas.
  • Malignant progression occurred in eight cases (32%) during the follow-up period; these cases were considered as a separate group.
  • The 3-year progression-free survival (PFS) rates for the Grades I, II, and III, and malignant progression groups were 100, 83, 0, and 11%, respectively (p < 0.001).
  • In the Grade II group, the 3-year PFS rates for patients treated with SRS and SRT were 100 and 33%, respectively (p = 0.1).
  • CONCLUSIONS: Stereotactic radiation treatment provided effective local control of "aggressive" Grade I and Grade II meningiomas, whereas Grade III lesions were associated with poor outcome.
  • The outcome of cases in the malignant progression group was intermediate between that of the Grade II and Grade III groups, with the lesions showing a tendency toward malignancy.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / pathology. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Reoperation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542529.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Sanai N, Sughrue ME, Shangari G, Chung K, Berger MS, McDermott MW: Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg; 2010 May;112(5):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk profile associated with convexity meningioma resection in the modern neurosurgical era.
  • OBJECT: Although meningiomas are commonly found along the supratentorial convexity, the risk profile associated with this subset of lesions in the modern neurosurgical era is unknown.
  • METHODS: The authors retrospectively reviewed the clinical course of patients with supratentorial convexity meningiomas treated during the past 10 years.
  • All patients had undergone MR imaging within 72 hours after surgery and at least 1 year of clinical follow-up.
  • Patients with multiple meningiomas, hemangiopericytomas, malignant meningiomas, or tumor-prone syndromes were excluded from analysis.
  • RESULTS: Between 1997 and 2007, 141 consecutive patients (median age 48 years, range 18-95 years) underwent resection of a supratentorial convexity meningioma.
  • The most common signs or symptoms at presentation were headache (48%), seizures (34%), and weakness (21%).
  • One hundred six tumors (75%) were WHO Grade I, whereas 35 (25%) were WHO Grade II.
  • The median clinical follow-up was 2.9 years (range 1-10 years), and the median radiographic follow-up was 3.7 years (range 1-10 years).
  • CONCLUSIONS: With the conservative recommendations for surgery for asymptomatic meningiomas and the advent of radiosurgery during the past 10 years, microsurgically treated convexity meningiomas are now typically large in size.
  • The authors' findings provide a defined risk profile associated with the resection of supratentorial convexity meningiomas in the modern neurosurgical era.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Neurosurgical Procedures / methods. Radiosurgery / methods. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Complications / epidemiology. Intraoperative Complications / prevention & control. Male. Microsurgery / instrumentation. Middle Aged. Risk Assessment. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645533.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Pelz AF, Klawunde P, Skalej M, Wieacker P, Kirches E, Schneider T, Mawrin C: Novel chromosomal aberrations in a recurrent malignant meningioma. Cancer Genet Cytogenet; 2007 Apr 1;174(1):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel chromosomal aberrations in a recurrent malignant meningioma.
  • The molecular basis of tumorigenesis and tumor progression in meningiomas is not fully understood.
  • Here we present results of conventional cytogenetic, fluorescence in situ hybridization (FISH), and comparative genetic hybridization (CGH) analyses in a patient with recurrent anaplastic meningioma.
  • We found complex aberrant karyotype alterations previously described in anaplastic meningiomas, such as 1p, 14q aberration, and a possibly tetraploid karyotype.
  • Additional chromosomal aberrations not previously reported included a near-triploid karyotype and alterations such as 4p+, 5p-, 7p+, 8q+, and gain of chromosome 19.
  • Our findings of several previously unreported cytogenetic alterations suggest that complex karyotype alterations are a characteristic feature in anaplastic meningiomas.
  • High chromosomal complexity might be associated with a highly aggressive meningioma phenotype.
  • [MeSH-minor] Adult. Chromosomes, Human / genetics. Genome, Human. Humans. In Situ Hybridization, Fluorescence. Recurrence

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350466.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K: Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg; 2006 Dec;105(6):898-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for recurrent malignant meningioma. Case report.
  • Malignant meningioma is a rare brain tumor with a high risk of recurrence.
  • The authors report the first case of recurrent malignant meningioma treated using boron neutron capture therapy (BNCT).
  • This 25-year-old pregnant woman presented with a large frontal tumor.
  • A second resection and three Gamma Knife surgeries could not control progression of the enhancing mass; therefore, the authors applied BNCT based on their experience with it in the treatment of malignant gliomas.
  • The treatment of recurrent malignant meningioma is difficult and has been discouraging thus far.
  • [MeSH-major] Boron Neutron Capture Therapy. Cranial Irradiation. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pregnancy Complications, Neoplastic / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neurologic Examination. Positron-Emission Tomography. Pregnancy. Radiosurgery. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405262.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K: Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery; 2007 Jul;61(1):82-90; discussion 90-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for malignant tumors related to meningiomas.
  • OBJECTIVE: Malignant meningiomas, similar to glioblastomas, are difficult tumors to control.
  • We tried to control malignant tumors related to meningiomas by boron neutron capture therapy (BNCT).
  • METHODS: Since June 2005, we applied BNCT with 13 rounds of neutron irradiation to seven cases of malignant tumors related to meningiomas.
  • Three were anaplastic meningiomas, two were papillary meningiomas, one was an atypical meningioma, and one was a sarcoma transformed from a meningioma with cervical lymph node metastasis.
  • The atypical meningioma case showed a tumor-to-healthy brain ratio of 2.0.
  • Two of the three anaplastic meningiomas showed a complete response, and all six patients available for follow-up imaging showed radiographic improvements.
  • In this patient, a huge atypical meningioma arose from the falcotentorial junction and extended to the bilateral occipital lobes and brainstem; visual problems worsened after repetitive BNCT, with an increase in peritumoral edema.
  • CONCLUSION: Malignant meningiomas seem to be good candidates for BNCT.
  • [MeSH-minor] Adult. Brain Injuries / etiology. Brain Injuries / radionuclide imaging. Female. Humans. Male. Radiation Injuries / etiology. Radiation Injuries / radionuclide imaging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621022.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Grill J, Lamfers ML, van Beusechem VW, van der Valk P, Huisman A, Sminia P, Alemany R, Curiel DT, Vandertop WP, Gerritsen WR, Dirven CM: Oncolytic virotherapy of meningiomas in vitro with replication-competent adenovirus. Neurosurgery; 2005;56(1):146-53; discussion 153-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic virotherapy of meningiomas in vitro with replication-competent adenovirus.
  • OBJECTIVE: To evaluate the efficacy of the conditionally replicating adenovirus (Ad) Ad.d24 for oncolysis of benign and malignant meningiomas.
  • METHODS: Primary meningioma cells and organotypic spheroids were cultured from tumor biopsies of 12 consecutive unselected patients.
  • Four different Ads were constructed and tested on meningioma cells and spheroids: a replication-deficient Ad encoding the luciferase marker gene (Ad.Luc), a replication-competent Ad with complete E1 region (Ad.E1+), a replication-competent Ad encoding the luciferase gene in the E3 region (Ad.E1Luc), and a conditionally replicating Ad with an E1ACR2 deletion (Ad.d24).
  • Replication of the latter is restricted to cells with a defective retinoblastoma pathway, whereas Ad.E1+ and Ad.E1Luc can replicate in all human cells like a wild-type Ad.
  • Their oncolytic activity was compared in primary meningioma cells and spheroids by use of viability and outgrowth assays.
  • RESULTS: Adenoviral penetration into organotypic meningioma spheroids was detected with the replication-competent Ad.E1Luc, whereas infection with the replication-deficient Ad.Luc was limited to the outer layer of the spheroid.
  • Replication of the Ads and oncolysis was demonstrated in primary cell cultures of meningioma cells at high dose, i.e., greater than 50 plaque-forming units per cell.
  • At a lower dose of 5 plaque-forming units per cell, Ad.d24 kills meningioma cells more efficiently than Ad.E1+.
  • Infection of organotypic meningioma spheroids with Ad.d24 resulted in decreased viability and suppression of outgrowth as compared with untreated control spheroids.
  • CONCLUSION: Infection of meningioma cells and spheroids with replication-competent Ads results in efficient oncolysis.
  • The Ad modified to replicate selectively in retinoblast-mutant cells, Ad.d24, seemed to be an efficient oncolytic agent in benign, atypical, and malignant meningiomas.
  • [MeSH-major] Meningioma / therapy. Oncolytic Virotherapy
  • [MeSH-minor] Adenoviridae / physiology. Adult. Aged. Cells, Cultured. Humans. Middle Aged. Virus Replication

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617597.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Jiang WH, Xiao JY, Zhao SP, Xie ZH, Zhang H: Resection of extensive sellar tumors with extended endoscopic transseptal transsphenoidal approach. Eur Arch Otorhinolaryngol; 2007 Nov;264(11):1301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six months to 5 years follow up indicated that all 16 patients with the visual disturbances and 4 patients with endocrine impairments have recovered or improved.
  • One patient with malignant meningioma died due to recurrence of the tumor 2 years postoperation.
  • Another one patient with malignant inverted papilloma recurred 1 year postoperation and underwent operation and radiation therapy again.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):956-62 [7499948.001]
  • [Cites] Neurosurgery. 2002 Sep;51(3):699-705; discussion 705-7 [12188948.001]
  • [Cites] Minim Invasive Neurosurg. 2001 Mar;44(1):1-12 [11409304.001]
  • [Cites] Kurume Med J. 1998;45(1):53-7 [9658751.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Sep;61(3B):836-41 [14595492.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS75-83; discussion ONS75-83 [16888556.001]
  • [Cites] Neurosurgery. 1997 Sep;41(3):602-7 [9310977.001]
  • [Cites] Surg Neurol. 2000 Feb;53(2):168-72; discussion 172-3 [10713196.001]
  • [Cites] Neurosurg Focus. 1996 Jul 15;1(1):e1; discussion 1p following e3 [15095996.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):1028-35 [10839266.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(4):343-7; discussion 347-8 [9202775.001]
  • [Cites] Neurol Res. 2002 Apr;24(3):259-65 [11958419.001]
  • [Cites] J Laryngol Otol. 1994 Jan;108(1):19-22 [8133158.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Nov;127(5):409-16 [12447234.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):225-36; discussion 236-7 [9007854.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):140-2 [3783248.001]
  • [Cites] Br J Neurosurg. 1994;8(2):193-6 [7917091.001]
  • [Cites] Am J Rhinol. 1998 Jul-Aug;12(4):283-7 [9740924.001]
  • [Cites] J Neurosurg. 1997 Jul;87(1):44-51 [9202264.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1487-90 [11115288.001]
  • [Cites] Laryngoscope. 1992 Feb;102(2):198-202 [1738293.001]
  • [Cites] Laryngoscope. 1996 Jul;106(7):914-8 [8667994.001]
  • [Cites] Clin Neurosurg. 1969;16:185-217 [5811707.001]
  • [Cites] Neurosurgery. 1997 May;40(5):944-6 [9149252.001]
  • [Cites] Surg Neurol. 1997 Mar;47(3):213-22; discussion 222-3 [9068690.001]
  • [Cites] Mayo Clin Proc. 1999 Jul;74(7):661-70 [10405694.001]
  • (PMID = 17549504.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Toktas ZO, Akgun E, Ozkan A, Bozkurt SU, Bekiroglu N, Seker A, Konya D, Kilic T: Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study. Neurosurgery; 2010 Dec;67(6):1724-32; discussion 1732
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study.
  • BACKGROUND: Intracranial meningiomas constitute approximately one fourth of all primary intracranial tumors.
  • The invention of cranial angiographic techniques has led to the recognition of the angiogenic potential of meningiomas, which has been the subject of extensive research.
  • OBJECTIVE: To test the relationship between the angiogenetic potential of intracranial meningiomas and clinical/prognostic features such as World Health Organization (WHO) grade, peritumoral edema, tumor border shape, and recurrence using rat corneal angiogenesis assay.
  • METHODS: Fifteen WHO grade I (typical), 10 WHO grade II (atypical), and 5 WHO grade III (malignant) meningioma samples were implanted in the micropockets formed on rat corneas, and the number of developed vessels were counted on days 5, 10, 15, and 20.
  • CONCLUSION: Our findings, based on a dynamic in vivo model to examine angiogenesis, demonstrate that the angiogenic potential of meningiomas is correlated with WHO grade, recurrence, and possibly with tumor border shape and peritumoral edema.
  • Angiogenesis seems to be an important factor in the natural course of meningiomas, suggesting that inhibition of angiogenesis may be an option, particularly in the treatment of meningiomas with an aggressive course.
  • [MeSH-major] Corneal Neovascularization / etiology. Corneal Neovascularization / pathology. Meningeal Neoplasms / complications. Meningioma / complications
  • [MeSH-minor] Adult. Animals. Brain Edema / etiology. Disease Models, Animal. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Rats. Rats, Sprague-Dawley. Retrospective Studies. Time Factors. Tissue Transplantation / methods. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21107204.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW: Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg; 2010 Aug;113(2):202-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.
  • OBJECT: Despite an increased understanding of the biology of malignant meningioma tumor progression, there is a paucity of published clinical data on factors affecting outcomes following treatment for these lesions.
  • METHODS: The authors identified all patients undergoing resection of WHO Grade III tumors at their institution over a 16-year period.
  • The median clinical follow-up time was 5 years (range 1-22 years).
  • The 2-, 5-, and 10-year overall survival rates following initial operation were 82, 61, and 40%, respectively.
  • Kaplan-Meier analysis demonstrated a marked survival benefit with repeat operation (53 vs 25 months, p = 0.02).
  • Twelve (19%) of 63 patients experienced significant neurological morbidity referable to the resection of their tumors.
  • CONCLUSIONS: Surgery is an effective treatment for WHO Grade III meningiomas at presentation and recurrence; however, aggressive attempts to achieve gross-total resection can be associated with significant neurological risk.
  • [MeSH-major] Meningeal Neoplasms. Meningioma. Neoplasm Recurrence, Local. Reoperation / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Morbidity. Proportional Hazards Models. Risk Factors. Severity of Illness Index. Treatment Outcome. World Health Organization. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Aug;113(2):199-200; discussion 200-1 [20225919.001]
  • [CommentIn] J Neurosurg. 2015 Jun;122(6):1514-5 [25859809.001]
  • (PMID = 20225922.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Bledsoe JM, Link MJ, Stafford SL, Park PJ, Pollock BE: Radiosurgery for large-volume (&gt; 10 cm3) benign meningiomas. J Neurosurg; 2010 May;112(5):951-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for large-volume (> 10 cm3) benign meningiomas.
  • OBJECT: Stereotactic radiosurgery (SRS) has proven to be a safe and effective treatment for many patients with intracranial meningiomas.
  • Nevertheless, the morbidity associated with radiosurgery of larger meningiomas is poorly understood.
  • METHODS: The authors performed a retrospective review of 116 patients who underwent SRS for meningiomas (WHO Grade I) > 10 cm3 between 1990 and 2007, with a minimum follow-up of 12 months.
  • Patients with atypical or malignant meningiomas and those who received prior radiotherapy were excluded.
  • RESULTS: Tumor control was 99% at 3 years and 92% at 7 years after radiosurgery.
  • Patients with supratentorial tumors experienced a higher complication rate compared with patients with skull base tumors (44% compared with 18%) (hazard ratio 2.9, 95% CI 1.3-6.7, p = 0.01).
  • CONCLUSIONS: The morbidity associated with SRS for patients with benign meningiomas > 10 cm(3) is greater for supratentorial tumors compared with skull base tumors.
  • Whereas radiosurgery is relatively safe for patients with large-volume skull base meningiomas, resection should remain the primary disease management for the majority of patients with large-volume supratentorial meningiomas.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery / instrumentation. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ataxia / epidemiology. Ataxia / etiology. Cerebral Infarction / epidemiology. Cerebral Infarction / etiology. Female. Follow-Up Studies. Headache / epidemiology. Headache / etiology. Hearing Disorders / epidemiology. Hearing Disorders / etiology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Dec;113(6):1335-6; author reply 1336-7 [20887089.001]
  • (PMID = 19764829.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Arivazhagan A, Devi BI, Kolluri SV, Abraham RG, Sampath S, Chandramouli BA: Pediatric intracranial meningiomas--do they differ from their counterparts in adults? Pediatr Neurosurg; 2008;44(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric intracranial meningiomas--do they differ from their counterparts in adults?
  • AIM: Meningiomas are very rare in children comprising only 0.44.1% of pediatric age tumors and only 1.5-1.8% of all intracranial neoplasms.
  • We analyzed the clinical, pathological and management profile of these rare tumors and elucidated their differences from meningiomas in adults.
  • METHODS: From 1990 to 2005, 33 patients belonging to the pediatric age group with intracranial meningiomas were treated in NIMHANS.
  • RESULTS: There were 19 male and 14 female children.
  • Intraventricular meningiomas were the commonest (24.2%).
  • Fibrous meningioma was the commonest histological subtype (24.2%).
  • Five patients had atypical or anaplastic subtypes.
  • CONCLUSION: Pediatric meningiomas are rare tumors and differ from those in adults by their male predominance, atypical locations, higher rates of malignant subtypes, recurrence and association with neurofibromatosis.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18097190.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


48. Ramina R, Neto MC, Fernandes YB, Aguiar PH, de Meneses MS, Torres LF: Meningiomas of the jugular foramen. Neurosurg Rev; 2006 Jan;29(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas of the jugular foramen.
  • Primary meningiomas of the jugular foramen are extremely rare.
  • From a series of 107 patients that had been operated on for jugular foramen tumors between 1987 and 2005, ten had meningiomas.
  • A high incidence of malignant or aggressive tumors (six cases) was found.
  • Four patients with meningotheliomatous meningiomas are alive, with a mean follow-up time of 71.8 months (6.5 years).
  • Two patients (one with anaplastic type and one with papillary type) died in the immediate postoperative period.
  • Four patients (two with papillary type, one with microcystic type and one with anaplastic type) died because of disease progression, with a mean survival time of 35 months.
  • Radical removal of benign jugular foramen meningiomas is possible.
  • A high incidence of aggressive (malignant) tumors was observed in this series.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Adult. Child. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neurosurgical Procedures. Occipital Bone. Temporal Bone. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otol. 1996 Jul;17(4):658-68 [8841718.001]
  • [Cites] Arq Neuropsiquiatr. 2004 Dec;62(4):997-1003 [15608958.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):373-7 [14736665.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Feb;106(2):128-36 [1738543.001]
  • [Cites] No Shinkei Geka. 1989 Jan;17 (1):87-92 [2651958.001]
  • [Cites] Otolaryngol Head Neck Surg (1979). 1979 Sep-Oct;87(5):578-83 [503520.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Neurosurg. 1995 Nov;83(5):903-9 [7472562.001]
  • [Cites] Laryngoscope. 2004 Jan;114(1):25-32 [14709990.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):279-84 [8545782.001]
  • [Cites] Laryngoscope. 1984 Jun;94(6):772-8 [6727514.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] Am J Clin Pathol. 1989 Sep;92(3):266-72 [2476026.001]
  • [Cites] Neurosurg Focus. 2004 Aug 15;17(2):E5 [15329020.001]
  • [Cites] Otolaryngol Clin North Am. 1982 Nov;15(4):897-916 [6298686.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurgery. 2005 Apr;56(2 Suppl):337-43; discussion 337-43 [15794830.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):624-7 [1374854.001]
  • [Cites] Cancer. 1975 Oct;36(4):1363-73 [1175134.001]
  • [Cites] Surg Neurol. 1998 Dec;50(6):563-70 [9870817.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1014-24 [15200116.001]
  • [Cites] Surg Neurol. 1989 Apr;31(4):295-9 [2928924.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):59-68; discussion 59-68 [15987570.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):299-305 [3719522.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):143-7 [15696976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):501-4 [3042721.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Laryngorhinootologie. 1991 Jun;70(6):284-8 [1872929.001]
  • [Cites] Am J Surg. 1960 Sep;100:486-9 [13716296.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):12-20 [12134902.001]
  • [Cites] J Neurosurg Sci. 1997 Sep;41(3):283-92 [9444582.001]
  • [Cites] Minim Invasive Neurosurg. 2001 Dec;44(4):211-7 [11830780.001]
  • (PMID = 16195869.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien); 2010 Oct;152(10):1711-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas.
  • OBJECT: 5-aminolevulinic acid (5-ALA) has gained importance as an intraoperative photodynamic diagnostic agent for the extirpation of malignant gliomas.
  • The application of this technique for resection of meningiomas has barely been explored.
  • The aim of this study was to evaluate the utility of 5-ALA-induced fluorescence as a visual tool in meningioma resection and its correlation with histological findings.
  • METHODS: A total of 33 consecutive patients undergoing resection of intracranial meningiomas from December 2007 to August 2009 were included in this study.
  • RESULTS: A total of 32 (97%) patients presented with benign meningiomas (WHO I-II).
  • In 1 (3%) patient, histological anaplastic signs (WHO III) could be demonstrated.
  • A total resection could be postoperatively demonstrated in 25 (76%) patients.
  • CONCLUSIONS: 5-ALA-induced fluorescence is a useful and promising intraoperative tool for the visualization of meningioma tissue.
  • The novel findings demonstrated in this study in terms of high fluorescence and poor correlation with histological findings highlight the usefulness of this technique as a routine visual tool to achieve optimal resection of meningiomas.
  • [MeSH-major] Aminolevulinic Acid. Fluorescence. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Monitoring, Intraoperative / methods. Photosensitizing Agents
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Recurrence, Local / prevention & control. Preoperative Care / methods. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535506.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


50. Shah AB, Muzumdar GA, Chitale AR: Meningiomas: report of a hospital-based registry. Indian J Pathol Microbiol; 2005 Oct;48(4):468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas: report of a hospital-based registry.
  • This is a hospital-based epidemiologic study of meningiomas.
  • Of 1321 central nervous system tumours, meningiomas constituted 21% of the cases, being the second largest category of a single histologic type after astrocytomas.
  • Of the 267 meningiomas studied, 247 were intra-cranial (92.5%).
  • The age of the patients varied between 6 to 84 years.
  • 261 (98%) meningiomas were histologically benign and 5 were malignant meningiomas (1.9%).
  • A 5-year follow-up was available in most cases, with the help of which it was possible to understand the biological behaviour of various sub-types and the influence of other parameters such as location and treatment schedules.
  • Of note was the fact, that out of 261 patients with benign meningiomas, 11 succumbed in the immediate post-operative period and in 8 of these cases, the tumour was located at the base of the skull.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Hospitals. Humans. Immunohistochemistry. India / epidemiology. Male. Middle Aged. Prognosis. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366096.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


51. Kim EY, Weon YC, Kim ST, Kim HJ, Byun HS, Lee JI, Kim JH: Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients. AJNR Am J Neuroradiol; 2007 Sep;28(8):1462-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients.
  • BACKGROUND AND PURPOSE: Rhabdoid meningioma (RM) is a recently described variant of malignant meningioma, with radiologic features currently not well characterized in the medical literature.
  • MATERIALS AND METHODS: CT (n = 8) and MR (n = 15) images of 15 patients (4 men and 11 women; mean age, 52 years; range, 22-75 years) with 16 pathologically proved RMs along with associated clinical records were retrospectively reviewed.
  • RESULTS: Nine lesions (56%) were located in the cerebral convexity, and 4 lesions (25%) were located in the parasagittal areas.
  • [MeSH-major] Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / physiopathology. Meningioma / diagnosis. Meningioma / physiopathology
  • [MeSH-minor] Adult. Aged. Cysts / diagnosis. Edema / chemically induced. Edema / etiology. Female. Follow-Up Studies. Humans. Hyperostosis / diagnosis. Hyperostosis / etiology. Male. Middle Aged. Neurosurgical Procedures. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846191.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Krayenbühl N, Pravdenkova S, Al-Mefty O: De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome. Neurosurgery; 2007 Sep;61(3):495-503; discussion 503-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome.
  • OBJECTIVE: The clinical course of atypical and anaplastic meningiomas is heterogeneous.
  • As malignant gliomas, aggressive meningiomas may arise de novo or transform from a benign tumor.
  • This study aims to compare differences in clinical behavior, cytogenetics, cytokinetics, receptor status, and outcome between de novo malignant meningiomas and meningiomas that progressed to malignancy.
  • METHODS: Data from 36 patients with atypical or anaplastic meningiomas were selected for retrospective analysis and divided into two subgroups:.
  • 1) de novo atypical or anaplastic tumors and 2) tumors that progressed from a lower grade.
  • For meningiomas with progression, we calculated the interval between initial diagnosis and tumor progression.
  • RESULTS: For atypical meningiomas, the subgroups had significant differences in status of progesterone receptors, proliferative indices, cytogenetics, and patients' outcome.
  • The anaplastic group had similar differences, but they did not reach statistical significance because of the small numbers.
  • These phenomena occurred mainly in patients with malignant transformation who had a worse outcome.
  • CONCLUSION: De novo malignant meningiomas and meningiomas with malignant transformation may represent distinct subgroups of atypical and anaplastic meningiomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cytogenetic Analysis / methods. Meningioma / genetics. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881961.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Nagar VA, Ye JR, Ng WH, Chan YH, Hui F, Lee CK, Lim CC: Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol; 2008 Jun;29(6):1147-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation.
  • BACKGROUND AND PURPOSE: Atypical and malignant meningiomas are uncommon tumors with aggressive behavior and higher mortality, morbidity, and recurrence compared with benign tumors.
  • We investigated the utility of diffusion-weighted (DW) MR imaging to differentiate atypical/malignant from benign meningiomas and to detect histologic dedifferentiation to higher tumor grade.
  • MATERIALS AND METHODS: We retrospectively compared conventional and DW MR images (b-value 1000 s/mm(2)) acquired on a 1.5T clinical scanner between 25 atypical/malignant and 23 benign meningiomas.
  • RESULTS: Irregular tumor margins, peritumoral edema, and adjacent bone destruction occurred significantly more often in atypical/malignant than in benign meningiomas.
  • The mean ADC of atypical/malignant meningiomas (0.66 +/- 0.13 x 10(-3) mm(2)/s) was significantly lower compared with benign meningiomas (0.88 +/- 0.08 x 10(-3) mm(2)/s; P < .0001).
  • Mean NADC ratio in the atypical/malignant group (0.91 +/- 0.18) was also significantly lower than the benign group (1.28 +/- 0.11; P < .0001), without overlap between groups.
  • Two patients had isointense benign tumors on initial DW MR imaging, and these became hyperintense with the decrease in ADC and NADC below these thresholds when they progressed to atypical and malignant meningiomas on recurrence.
  • CONCLUSIONS: ADC and NADC ratios in atypical/malignant meningiomas are significantly lower than in benign tumors.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Cell Dedifferentiation. Female. Humans. Male. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2009 Feb;30(2):E21 [19193747.001]
  • (PMID = 18356472.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Söling A, Plugge EM, Schmitz M, Weigle B, Jacob R, Illert J, Holzhausen HJ, Rainov NG: Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol; 2007 Jan;30(1):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survivin is a member of the inhibitor of apoptosis protein (IAP) family and is frequently expressed in cancers, including meningiomas and gliomas.
  • Using ELISA and immunoblot analysis we asked whether survivin is capable of eliciting a humoral immune response in patients with meningiomas and gliomas.
  • Survivin-specific antibodies were detected in 5 of 42 (11.9%) patients with meningiomas and 3 of 35 (8.6%) patients with malignant gliomas of the WHO grades 3 and 4, but not in healthy controls.
  • We conclude that patients with meningiomas and malignant gliomas can mount a high-titer IgG immune response against the 'universal' tumor-associated antigen survivin.
  • Anti-survivin antibodies may represent attractive tools for diagnosis and follow-up of brain tumors.
  • [MeSH-minor] Adult. Aged. Apoptosis / immunology. Glioma / immunology. Glioma / pathology. Humans. Immunoglobulin G / blood. Inhibitor of Apoptosis Proteins. Meningioma / immunology. Meningioma / pathology. Middle Aged. Neoplasm Staging. Recombinant Proteins / immunology. Reference Values

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143520.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / BIRC5 protein, human; 0 / Immunoglobulin G; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Recombinant Proteins
  •  go-up   go-down


55. Mattei TA, Mattei JA, Ramina R, Aguiar PH, Plese JP, Marino Jr R: Edema and malignancy in meningiomas. Clinics (Sao Paulo); 2005 Jun;60(3):201-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Edema and malignancy in meningiomas.
  • PURPOSE: In recent years there have been many attempts to define a subset of aggressive malignant meningiomas based on histopathology and imaging technologies.
  • METHODS: The cases of 55 patients with meningiomas who underwent surgery at the Hospital das Clinicas (Fac Med Univ Sao Paulo) between September 1993 and September 1997 were reviewed.
  • RESULTS: Classification of the degree of edema was: level 0 edema--28 cases ; level I edema--19 cases; level II edema--8 cases.
  • Histological classification was: benign meningioma--43 cases; atypical meningiomas--11 cases; malignant meningioma--1 case.
  • CONCLUSIONS: These results suggest that the degree of edema as revealed by computer tomography and magnetic resonance imaging can be an important clinical predictive factor for the histological grade of the meningioma.
  • [MeSH-major] Brain Edema / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Severity of Illness Index. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962080.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


56. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged


57. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust P, Stockhammer F, Röttgen R, Gutberlet M, Ruf J, Felix R: Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology; 2005 Jan;47(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.
  • The value of single-photon emission tomography (SPECT) using iodine-123-alpha-methyl-tyrosine (IMT) for the diagnosis of recurrent or residual gliomas is well established.
  • The study included 22 patients with suspected recurrent intracranial tumours of non-astrocytic origin (12 brain metastases, one supratentorial primitive neuroendocrine tumour (PNET), one rhabdoid tumour, two clivus chordomas, three ependymomas, two pituitary tumours, one anaplastic meningioma) who had previously been treated by surgery and/or radio/chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Aged. Chordoma / diagnostic imaging. Ependymoma / diagnostic imaging. False Negative Reactions. False Positive Reactions. Female. Follow-Up Studies. Glioma / diagnostic imaging. Humans. Magnetic Resonance Imaging. Male. Meningioma / diagnostic imaging. Middle Aged. Neuroendocrine Tumors / diagnostic imaging. Pituitary Neoplasms / diagnostic imaging. Retrospective Studies. Rhabdoid Tumor / diagnostic imaging. Sensitivity and Specificity. Supratentorial Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2001 Apr;42(4):579-85 [11337545.001]
  • [Cites] Acta Radiol. 1989 Mar-Apr;30(2):121-8 [2493795.001]
  • [Cites] Ann Nucl Med. 2002 Nov;16(7):503-6 [12508845.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):49-58 [15527107.001]
  • [Cites] AJR Am J Roentgenol. 1994 Dec;163(6):1459-65 [7992747.001]
  • [Cites] Eur J Nucl Med. 1998 Feb;25(2):177-81 [9473267.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1793-800 [11079485.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):801-19 [10517946.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):396-404 [11786566.001]
  • [Cites] Eur J Nucl Med. 1999 Feb;26(2):144-51 [9933348.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):162-71 [8153662.001]
  • [Cites] Nuklearmedizin. 1995 Apr;34(2):71-5 [7761277.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] J Nucl Med. 1989 Jan;30(1):110-2 [2783455.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10 ):1736-43 [9776279.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):23-7 [9443732.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14 (3):524-7 [8517335.001]
  • [Cites] Nucl Med Commun. 1996 Mar;17 (3):197-8 [8692485.001]
  • [Cites] J Nucl Med. 1997 Apr;38(4):517-22 [9098193.001]
  • [Cites] Radiology. 1993 Jan;186(1):37-44 [8416584.001]
  • [Cites] Acta Radiol. 1990 Sep;31(5):417-29 [2261284.001]
  • [Cites] Radiology. 2003 Jan;226(1):181-7 [12511688.001]
  • [Cites] Nuklearmedizin. 1997 Mar;36(2):36-41 [9148271.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):374-81 [15001676.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):28-33 [8355844.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] Curr Opin Oncol. 1994 May;6(3):254-61 [8080854.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):579-86 [15073253.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54 [12377338.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2252-9 [10873075.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] Nucl Med Commun. 1996 Jul;17 (7):609-15 [8843121.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Nuklearmedizin. 2002;41(4):191-6 [12224403.001]
  • [Cites] Ann Neurol. 1991 Apr;29(4):347-55 [1929205.001]
  • [Cites] J Nucl Med. 1990 Mar;31(3):281-6 [2155314.001]
  • (PMID = 15630586.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 0 / Radiopharmaceuticals; A77N8J5H5T / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


58. Goh KY, Poon WS, Chan DT, Ip CP: Tissue plasminogen activator expression in meningiomas and glioblastomas. Clin Neurol Neurosurg; 2005 Jun;107(4):296-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue plasminogen activator expression in meningiomas and glioblastomas.
  • OBJECTIVES: Enzyme-linked immunosorbent assay (ELISA) and Western blotting techniques were used to investigate and compare the expression of tissue plasminogen activator (tPA) in benign (meningioma) and malignant (glioblastoma) human brain tumours.
  • METHODS: A total of 22 tumour samples comprising 11 meningiomas and 11 glioblastomas with adjacent peritumoural tissue were analysed.
  • RESULTS: The mean tPA content of meningiomas was approximately half that of glioblastomas (55.40 (S.D.
  • Comparing tPA quantity in tumour and peritumoural tissue, there was a significant difference for meningiomas (55.40 (S.D.
  • Comparing tumour with normal brain tissue, there was no difference for meningiomas (55.40 (S.D.
  • 21.55) ng/ml, p=0.22), but a significant difference for glioblastomas (106.98 (S.D.
  • 21.55) ng/ml, p=0.004).
  • Western blotting showed that in the meningioma group, the molecular weight pattern was constant with a dominant well-defined band at 41kD.
  • CONCLUSION: These results indicate that (1) tPA is present in larger quantities in glioblastoma compared to meningioma and normal brain, (2) tPA quantity is not significantly different in the peritumoural tissue adjacent to glioblastoma but is significantly less for meningioma, and (3) tPA is expressed in more heterogenous forms in glioblastoma.
  • This present study therefore suggests that the expression of tPA in a brain tumour may be an additional prognostic factor in terms of its malignant and invasive potential.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Meningeal Neoplasms / enzymology. Meningioma / enzymology. Tissue Plasminogen Activator / metabolism
  • [MeSH-minor] Adult. Aged. Brain / enzymology. Brain / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885387.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


59. Korenkov AI, Imhof HG, Brandner S, Taub E, Huguenin PU, Gaab MR, Yonekawa Y: Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature. J Neurooncol; 2005 Sep;74(2):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature.
  • We report a case of meningioma diagnosed 23 years after high-dose cranial and whole-body irradiation for the treatment of acute lymphocytic leukemia (ALL).
  • Radiation-induced meningiomas are more commonly malignant, more commonly multiple, and more likely to recur after resection than non-radiation-induced meningiomas.
  • Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.
  • [MeSH-major] Cataract / etiology. Cranial Irradiation / adverse effects. Growth Disorders / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Humans. Lens, Crystalline / radiation effects. Magnetic Resonance Imaging. Male. Pituitary Gland / radiation effects. Time Factors. Tomography, X-Ray Computed. Whole-Body Irradiation


60. Maheshwar A, Steward DL: Malignant meningioma of the parapharyngeal space: a rare case. Otolaryngol Head Neck Surg; 2005 Jan;132(1):144-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma of the parapharyngeal space: a rare case.
  • [MeSH-major] Head and Neck Neoplasms. Meningioma
  • [MeSH-minor] Adult. Humans. Male. Pharynx

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632927.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C: The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS One; 2010;5(6):e11231
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential involvement of E-cadherin and beta-catenins in meningioma.
  • OBJECTIVE: To investigate the potential involvements of E-cadherin and beta-catenin in meningioma.
  • METHODS: Immunohistochemistry staining was performed on samples from patients with meningioma.
  • The expression of E-cadherin and beta-catenin in meningioma was analyzed by its relationship with WHO2007 grading, invasion, peritumoral edema and postoperative recurrence.
  • RESULTS: The positive rates of E-cadherin in meningioma WHO I, II, III were 92.69%, 33.33% and 0, respectively, (P<0.05); while the positive rates of beta-catenin in meningioma WHO I, II, III were 82.93%, 33.33% and 20.00%, respectively, (P<0.05).
  • The positive rate of E-cadherin in meningioma without invasion (94.12%) was higher than that with invasion (46.67%) (P<0.05).
  • The difference in the positive rate of beta-catenin between meningioma without invasion (88.24%) and meningioma with invasion (33.33%, P<0.05) was also statically significant.
  • The positive rates of E-cadherin in meningioma with peritumoral edema 0, 1, 2, 3 were 93.75%, 85.71%, 60.00% and 0 respectively, (P<0.05); the positive rates of beta-catenin in meningioma with peritumoral edema 0, 1, 2, 3 were 87.50%, 85.71%, 30.00% and 0 respectively, (P<0.01).
  • The positive rates of E- cadherin in meningioma with postoperative recurrence were 33.33%, and the positive rate with postoperative non-recurrence was 90.00% (P<0.01).
  • The positive rates of beta-catenin in meningioma with postoperative recurrence and non-recurrence were 11.11%, 85.00%, respectively (P<0.01).
  • CONCLUSION: The expression levels of E- cadherin and beta-catenin correlated closely to the WHO 2007 grading criteria for meningioma.
  • In atypical or malignant meningioma, the expression levels of E-cadherin and beta-catenin were significantly lower.
  • The expression levels of E- cadherin and beta-catenin were also closely correlated with the invasion status of meningioma, the size of the peritumoral edema and the recurrent probabilities of the meningioma, all in an inverse correlationship.
  • Taken together, the present study provided novel molecular targets in clinical treatments to meningioma.
  • [MeSH-major] Cadherins / metabolism. Meningioma / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Edema / complications. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Period. Recurrence. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Clin Neuropathol. 2005 Jan-Feb;24(1):8-12 [15696778.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Rev Med Chil. 2006 Aug;134(8):1002-9 [17130988.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5A):3083-9 [17970048.001]
  • [Cites] Int Urol Nephrol. 2007;39(4):1031-7 [17340210.001]
  • [Cites] Cell Tissue Res. 2008 Feb;331(2):401-12 [17965884.001]
  • [Cites] Biochem Soc Trans. 2008 Apr;36(Pt 2):141-7 [18363554.001]
  • [Cites] Genet Mol Res. 2008;7(2):295-304 [18551395.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] Mol Biosyst. 2008 Aug;4(8):835-50 [18633485.001]
  • [Cites] Trends Neurosci. 2008 Sep;31(9):487-94 [18684518.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):267-74 [18712413.001]
  • [Cites] Clin Neuropathol. 2008 Sep-Oct;27(5):334-45 [18808065.001]
  • [Cites] Surg Neurol. 2008 Nov;70(5):471-7; discussion 477 [18586307.001]
  • [Cites] Cell Commun Adhes. 2008 Nov;15(4):365-78 [18937087.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):489-92 [19051819.001]
  • [Cites] Cell Mol Life Sci. 2008 Nov;65(23):3756-88 [18726070.001]
  • [Cites] Genomics. 1995 Mar 20;26(2):281-9 [7601454.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):3-15 [15527101.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7951-7 [16258095.001]
  • (PMID = 20574529.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2888586
  •  go-up   go-down


62. Zhang H, Rödiger LA, Shen T, Miao J, Oudkerk M: Perfusion MR imaging for differentiation of benign and malignant meningiomas. Neuroradiology; 2008 Jun;50(6):525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion MR imaging for differentiation of benign and malignant meningiomas.
  • INTRODUCTION: Our purpose was to determine whether perfusion MR imaging can be used to differentiate benign and malignant meningiomas on the basis of the differences in perfusion of tumor parenchyma and/or peritumoral edema.
  • METHODS: A total of 33 patients with preoperative meningiomas (25 benign and 8 malignant) underwent conventional and dynamic susceptibility contrast perfusion MR imaging.
  • The independent samples t-test was used to determine whether there was a statistically significant difference in the mean rCBV and rMTE ratios between benign and malignant meningiomas.
  • RESULTS: The mean maximal rCBV values of benign and malignant meningiomas were 7.16+/-4.08 (mean+/-SD) and 5.89+/-3.86, respectively, in the parenchyma, and 1.05+/-0.96 and 3.82+/-1.39, respectively, in the peritumoral edema.
  • The mean rMTE values were 1.16+/-0.24 and 1.30+/-0.32, respectively, in the parenchyma, and 0.91+/-0.25 and 1.24+/-0.35, respectively, in the peritumoral edema.
  • The differences in rCBV and rMTE values between benign and malignant meningiomas were not statistically significant (P>0.05) in the parenchyma, but both were statistically significant (P<0.05) in the peritumoral edema.
  • CONCLUSION: Perfusion MR imaging can provide useful information on meningioma vascularity which is not available from conventional MRI.
  • Measurement of maximal rCBV and corresponding rMTE values in the peritumoral edema is useful in the preoperative differentiation between benign and malignant meningiomas.
  • [MeSH-major] Magnetic Resonance Angiography. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Blood Volume. Brain Edema / etiology. Brain Edema / physiopathology. Cerebrovascular Circulation / physiology. Contrast Media. Female. Gadolinium DTPA. Humans. Male. Middle Aged

  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Imaging. 2002 Jul-Aug;26(4):243-9 [12140153.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Sep;24(8):1554-9 [13679270.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jan-Feb;13(1):29-37 [1595462.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):481-4 [9167601.001]
  • [Cites] Neuroradiology. 2006 Dec;48(12):867-74 [17013587.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • [Cites] J Clin Neurosci. 2006 Jan;13(1):136-9 [16410217.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):409-17 [16484420.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]
  • [Cites] Cancer. 1998 May 1;82(9):1749-55 [9576298.001]
  • (PMID = 18379768.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2440923
  •  go-up   go-down


63. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus; 2007;23(4):E8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
  • OBJECT: The current treatment for recurrent or malignant meningiomas with adjuvant therapies has not been satisfactory, and there is an intense interest in evaluating new molecular markers to act as therapeutic targets.
  • Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas.
  • To find possible targets for chemotherapeutic intervention, the authors evaluated the expression of AA derivatives at different molecular levels in meningiomas.
  • METHODS: One hundred and twenty-four meningioma surgical specimens and normal human cortical tissue samples were immunohistochemically and cytochemically stained for COX-2, COX-1, 5-LO, and prostaglandin E receptor 4 (PTGER4).
  • RESULTS: Sixty (63%) of 95 benign meningiomas, 21 (88%) of 24 atypical meningiomas, all five malignant meningiomas, and all normal human cortex samples displayed high COX-2 immunoreactivity.
  • The PCR analysis demonstrated no changes in eicosanoid expression among meningiomas of different World Health Organization grades and in normal human cortical and dura mater tissue.
  • CONCLUSIONS: Eicosanoid derivatives COX-1, COX-2, 5-LO, and PTGER4 enzymes show a high universal expression in meningiomas but are not upregulated in normal human cortex and dura tissue.
  • This finding of the ubiquitous presence of these enzymes in meningiomas offers an excellent baseline for testing upcoming chemotherapeutic treatments.
  • [MeSH-major] Eicosanoids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arachidonate 5-Lipoxygenase / metabolism. Case-Control Studies. Female. Humans. Male. Middle Aged. Prostaglandin-Endoperoxide Synthases / metabolism. RNA, Messenger / metabolism. Receptors, Prostaglandin E / metabolism. Receptors, Prostaglandin E, EP4 Subtype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eicosanoids; 0 / PTGER4 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


64. Engenhart-Cabillic R, Farhoud A, Sure U, Heinze S, Henzel M, Mennel HD, Bertalanffy H: Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol; 2006 Nov;182(11):641-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
  • BACKGROUND AND PURPOSE: Although meningiomas are typically benign, they occasionally behave in an aggressive fashion and carry a less favorable prognosis.
  • PATIENTS AND METHODS: 16 patients with atypical meningiomas (n = 11) and anaplastic meningiomas (n = 5) were treated in the Departments of Neurosurgery and Radiation Oncology at the University Hospital of Philipps University Marburg, Germany, between 1997 and 2003.
  • There were eleven men and five women with a mean age of 54 years.
  • Patients with atypical meningioma received radiotherapy only for the recurrent disease.
  • Radiographic findings suggestive of aggressiveness were observed mostly with WHO grade III meningiomas.
  • By comparing the proliferation rate in four cases with atypical meningioma operated twice, the recurrent tumor had a higher proliferation rate than the first tumor in three cases.
  • A special proliferation pattern was noticed in MIB-1 with anaplastic meningiomas.
  • There was no mortality among patients with atypical meningioma, while four out of five patients with anaplastic meningioma died during follow-up.
  • CONCLUSION: Considering the higher rate of recurrence in aggressive meningiomas even after radical surgical excision and the possibility that the recurrent tumor is more aggressive than the original one, surgery should be combined with postoperative fractionated radiotherapy to improve local tumor control.
  • The peculiar focal expression patterns of anaplastic meningioma in MIB-1 might be a marker of such malignant development.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Male. Meninges / pathology. Microsurgery. Middle Aged. Neoplasm Recurrence, Local. Practice Guidelines as Topic. Prognosis. Radiotherapy Dosage. Sex Factors. Stereotaxic Techniques. Survival Analysis. Time Factors. World Health Organization

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072521.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


65. Morokoff AP, Zauberman J, Black PM: Surgery for convexity meningiomas. Neurosurgery; 2008 Sep;63(3):427-33; discussion 433-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for convexity meningiomas.
  • OBJECTIVE: Meningiomas that occur over the convexity of the brain are the most common meningiomas, but little has been published about their contemporary management.
  • We aimed to analyze a large series of convexity meningiomas with respect to surgical technique, complication rates, and pathological factors leading to recurrence.
  • METHODS: We retrospectively reviewed 163 cases of convexity meningiomas operated on in our institution by the senior author (PMB) between 1986 and 2005.
  • The median follow-up time was 2.3 years (range, 1-13 yr).
  • RESULTS: Convexity tumors represented 22% of all meningiomas operated on.
  • Median age was 57 years (range, 20-89 yr).
  • Image-guided surgery was used on all cases in the last 5 years.
  • The pathology of the tumors was benign in 144 (88.3%), atypical in 16 (9.8%), and anaplastic/malignant in 3 (1.8%).
  • The 5-year recurrence rate for benign meningiomas was 1.8%, atypical meningiomas 27.2%, and anaplastic meningiomas 50%.
  • The borderline atypical cases had a 5-year recurrence-free survival rate of only 55.9%, more closely approximating that of tumors designated "atypical."
  • CONCLUSION: Convexity meningiomas can be safely removed using modern image-guided minimally invasive surgical techniques with a very low operative mortality.
  • Benign convexity meningiomas having a Simpson Grade I complete excision have a very low recurrence rate.
  • The recurrence rates of atypical and malignant tumors are significantly higher, and borderline atypical tumors should be considered to behave more like atypical rather than benign lesions.
  • Longer-term follow-up data are needed to more accurately determine the recurrence rates of benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Craniotomy / methods. Craniotomy / mortality. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Survival Rate / trends. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812953.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Chen J, Xu X, Wang H: Expression of integrin-alpha(3) mRNA in meningiomas and its correlation with proliferation and invasion. J Huazhong Univ Sci Technolog Med Sci; 2009 Feb;29(1):94-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of integrin-alpha(3) mRNA in meningiomas and its correlation with proliferation and invasion.
  • To investigate the expression of integrin-alpha3 mRNA in meningiomas and its correlation with proliferation and invasion, the expression of integrin-alpha(3) subunit was detected by using in situ hybridization in patients with meningiomas (36 cases) and normal dura (2 cases) and arachnoid tissues (2 cases).
  • The results showed that the expression of integrin-alpha(3) mRNA in benign, atypical and malignant meningiomas was 2.52+/-0.362, 1.75+/-0.316 and 1.42+/-0.633, respectively.
  • The expression levels of integrin-alpha(3) mRNA was significantly lower in atypical or malignant meningiomas than those in benign meningiomas (P<0.05, P<0.01, respectively).
  • It suggested that integrin-alpha(3) subunit participated in the modulatory process of growth of meningiomas.
  • The proliferation activity and malignant grade of meningiomas were increased with the decreased expression of integrin-alpha(3) subunit, and the down-regulation of integrin-alpha(3) mRNA was associated with the invasive biological behaviors in meningiomas.
  • [MeSH-major] Integrin alpha3 / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / genetics. RNA, Messenger / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 2005;22(5):391-402 [16283482.001]
  • [Cites] Neurosurgery. 2000 Nov;47(5):1185-95 [11063113.001]
  • [Cites] Biochemistry (Mosc). 2003 Dec;68(12):1284-99 [14756624.001]
  • [Cites] Curr Opin Cell Biol. 2007 Oct;19(5):495-507 [17928215.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):283-95 [15263022.001]
  • [Cites] Mol Biol Cell. 1999 Feb;10(2):259-70 [9950675.001]
  • [Cites] Cytokine. 2007 Feb;37(2):163-70 [17481915.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):19-26 [12125963.001]
  • [Cites] Curr Med Chem. 2008;15(20):1968-75 [18691052.001]
  • [Cites] Exp Cell Res. 2007 Nov 1;313(18):3819-31 [17888902.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1272-81 [18224668.001]
  • [Cites] Annu Rev Immunol. 2007;25:619-47 [17201681.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1102-10 [10964341.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1060-7 [9508191.001]
  • (PMID = 19224172.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Integrin alpha3; 0 / RNA, Messenger
  •  go-up   go-down


67. Friedman WA, Murad GJ, Bradshaw P, Amdur RJ, Mendenhall WM, Foote KD, Bova FJ: Linear accelerator surgery for meningiomas. J Neurosurg; 2005 Aug;103(2):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear accelerator surgery for meningiomas.
  • OBJECT: In this paper the authors review the results of a single-center experience in the use of linear accelerator (LINAC) surgery for radiosurgical treatment of meningiomas.
  • METHODS: A retrospective analysis of all patients treated with LINAC surgery for meningiomas between May 1989 and December 2001 was performed.
  • All patients participated in follow-up review for a minimum of 2 years, and no patients were excluded.
  • The actuarial local control rate for benign tumors was 100% at both 1 and 2 years, and 96% at 5 years.
  • The actuarial local control rate for atypical tumors was 100% at 1 year, 92% at 2 years, and 77% at 5 years; and that for malignant tumors was 100% at both 1 and 2 years, and only 19% at 5 years.
  • In all patients with a permanent complication the histological characteristics of the meningioma were malignant.
  • CONCLUSIONS: Linear accelerator surgery produced high local control rates and very low rates of permanent morbidity in patients harboring benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Particle Accelerators. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 Aug;103(2):203-5; discussion 205 [16175846.001]
  • (PMID = 16175847.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Suwonpanich P, Laothamatas J: Magnetic resonance venography in intracranial veno-occlusive disease. J Med Assoc Thai; 2007 May;90(5):913-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance venography in intracranial veno-occlusive disease.
  • OBJECTIVE: To identify the common MR Vfindings in the patient diagnosed intracranial veno-occlusive disease at Ramathibodi Hospital and to identify the underlying conditions that probably predisposed the patient to the intracranial veno-occlusive disease.
  • MATERIAL AND METHOD: Sixty-four patients with clinically suggestive intracranial veno-occlusive disease who underwent MRV were reviewed in terms of signs and symptoms, MRV methods, MRV findings, and clinical diagnosis after report MRV In cases diagnosed to have intracranial veno-occlusive disease, the patients' records were reviewed to identify predisposing conditions.
  • RESULTS: Thirty-four patients were diagnosed to have intracranial veno-occlusive disease.
  • Contributing factors in patients diagnosed to have intracranial veno-occlusive disease in the present series were birth control pill in take, tumor (meningioma, and malignant schwannoma of the scalp), blood dyscrasia, AVM, hypotension, and abscess.
  • The causes of intracranial venous thrombosis could not be identified in seven patients (21%).
  • CONCLUSION: The common MR Vfinding in acute intracranial veno-occlusive disease was lack of typical high flow signal from a sinus while frayed appearance of flow signal from a sinus was the common direct sign in chronic condition.
  • [MeSH-major] Cerebrovascular Disorders / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Phlebography. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17596045.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


69. Adeolu AA, Sutherland GR: Intraoperative magnetic resonance imaging and meningioma surgery. West Afr J Med; 2006 Jul-Sep;25(3):174-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative magnetic resonance imaging and meningioma surgery.
  • OBJECTIVE: To determine if intraoperative magnetic resonance imaging improves surgical resection and postoperative outcome of intracranial meningioma.
  • METHOD: Intraoperative Magnetic Resonance Imaging (iMRI) was used to evaluate patients with meningioma undergoing surgery.
  • Extent of surgical resection was graded using Simpson grading system for meningioma.
  • Primary outcome measure was determined by finding unexpected tumur in interdissection images.
  • Two of these patients had anaplastic meningioma.
  • [MeSH-major] Magnetic Resonance Imaging. Meningeal Neoplasms / surgery. Meningioma / surgery. Surgery, Computer-Assisted
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191414.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


70. Nakamura Y, Shimizu T, Ohigashi Y, Itou N, Ishikawa Y: Meningioma arising in Werner syndrome confirmed by mutation analysis. J Clin Neurosci; 2005 May;12(4):503-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma arising in Werner syndrome confirmed by mutation analysis.
  • OBJECTIVE AND IMPORTANCE: Meningioma arising in Werner syndrome has been described previously, but never in association with a mutation analysis.
  • We present the first reported case of meningioma in a patient with Werner syndrome and a confirmed major mutation.
  • In addition, we review 27 previously reported patients with meningioma associated with Werner syndrome.
  • CLINICAL PRESENTATION: We report a 56-year-old Japanese woman with Werner syndrome and a meningioma.
  • Pathological examination after surgical removal confirmed meningioma.
  • INVESTIGATION: To confirm the clinical diagnosis, a mutation analysis based on the mutant allele-specific amplification (MASA) method was performed.
  • There were 22 patients with Werner syndrome and meningioma reported from Japan and 5 from outside Japan.
  • There was only one malignant meningioma.
  • Meningiomas in Werner syndrome have a higher frequency in males and occur at a younger age than those of the general population.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningioma / genetics. Mutation. Werner Syndrome / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction / methods. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Werner's syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925797.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


71. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry; 2008 May;79(5):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
  • OBJECTIVES: To evaluate patient outcome and investigate the prognostic factors of high-grade meningiomas by adopting the 2000 World Health Organization (WHO) classification system.
  • METHODS: Between 1986 and 2004, 74 patients were diagnosed with high-grade meningioma: 33 with atypical and 41 with anaplastic meningioma.
  • RESULTS: Forty of 74 meningiomas were reclassified as atypical meningioma and 24 as anaplastic meningioma.
  • Overall and recurrence-free survivals were significantly longer in patients with atypical than in those with anaplastic meningioma: 142.5 versus 39.8 months and 138.5 versus 32.2 months, respectively (p<0.001).
  • In patients with atypical meningiomas, brain invasion and adjuvant radiotherapy were not associated with survival; however, in the brain invasion subgroup, adjuvant radiotherapy improved patients' survival.
  • In patients with anaplastic meningioma, the prognostic factors were brain invasion, adjuvant radiotherapy, malignant progression, p53 overexpression and extent of resection.
  • The p53 overexpression was the only factor associated with malignant progression (p = 0.009).
  • CONCLUSIONS: The 2000 WHO classification has identified the truly aggressive meningiomas better than did the previous criteria.
  • A precise meningioma grading system may help to avoid over-treatment of patients with an atypical meningioma as, once the tumour has "declared itself" by recurrence and histological features, it becomes a tumour that is poorly amenable to current therapies.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Aged. Brain / pathology. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / genetics. Humans. Ki-67 Antigen / genetics. Korea. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / classification. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / genetics. World Health Organization

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766430.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


72. Li XZ, Zhao JZ: [Operation of lateral ventricular meningiomas of the trigone]. Zhonghua Yi Xue Za Zhi; 2006 Sep 5;86(33):2321-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operation of lateral ventricular meningiomas of the trigone].
  • OBJECTIVE: To summarize the surgical treatment of intraventricular trigonal meningiomas.
  • METHOD: 64 cases of intraventricular trigonal meningiomas were retrospectively analyzed.
  • Pathological diagnosis included 35 fibrous, 10 mixed, 8 endothelial, 3 transitional, 1 secretion and 1 malignant meningioma.
  • CONCLUSION: Transcortical parieto-occipital approach and Transcortical temporo-parieto-occipital approaches are applicable for intraventricular trigonal meningiomas.
  • [MeSH-major] Lateral Ventricles / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Humans. Male. Microsurgery / methods. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156626.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


73. Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn KR, Lal A: Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res; 2007 Jan 1;13(1):68-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
  • Tumor hypoxia is often associated with more malignant phenotypes, resistance to therapy, and poor survival.
  • The purpose of this study was to evaluate the prevalence of hypoxia in meningiomas using the endogenous hypoxia marker carbonic anhydrase 9 (CA9) and to relate the expression of CA9 to tumor vascularity, histopathologic grade, and clinical variables, such as recurrent tumor status.
  • EXPERIMENTAL DESIGN: Expression of CA9 and CD34, an endothelial cell marker, was examined in serial paraffin-embedded sections by immunohistochemistry in 25 grade 1, 17 grade 2, and 20 grade 3 meningiomas.
  • RESULTS: Approximately 50% (29 of 62) of all meningiomas contained regions of hypoxia as judged by expression of CA9, and this expression was significantly associated with higher-grade histology (P = 0.001).
  • Among lower-grade meningiomas, CA9 expression tended to be more common in recurrent tumors.
  • CONCLUSIONS: Tumor hypoxia is an endogenous feature of meningiomas, and therapeutic regimens should include strategies to target the subpopulation of hypoxic as well as the normoxic cells within the tumor.
  • Hypoxia in meningiomas is associated with an aggressive phenotype.
  • Further studies to define the contribution of hypoxia to meningioma pathophysiology are warranted.
  • [MeSH-major] Anoxia. Antigens, Neoplasm / biosynthesis. Carbonic Anhydrases / biosynthesis. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Antineoplastic Agents / pharmacology. Female. Humans. Immunohistochemistry. Male. Microcirculation. Middle Aged. Phenotype. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200340.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


74. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP: Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci; 2010 May;17(5):584-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?
  • Atypical and malignant meningiomas are more likely to recur than benign meningiomas.
  • We aimed to distinguish atypical and malignant meningiomas from benign meningiomas based on imaging findings.
  • Between 2004 and 2007, a total of 75 patients with resected intracranial meningiomas were retrospectively reviewed.
  • Histopathological grades were assigned as benign and atypical/malignant meningiomas according to the World Health Organization (WHO) classification.
  • There were 59 benign and 16 atypical/malignant meningiomas.
  • Only intratumoral cystic change and extracranial tumor extension through the skull base foramina were more prevalent in atypical/malignant meningiomas (p=0.001).
  • Hence, these two imaging features might be potential markers of atypical/malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Male. Middle Aged. Patient Selection. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219376.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


75. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenesis.
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.
  • Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible.
  • Of 19 patients evaluable for response, 10 progressed at the first scan, and 9 were stable.
  • For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.
  • For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%.
  • Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


76. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res; 2010 Aug 15;16(16):4155-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
  • PURPOSE: Meningiomas are the most common central nervous system tumors in the population of age 35 and older.
  • Clinical data supporting histologic malignant progression of meningiomas are sparse and underlying molecular mechanisms are not clearly depicted.
  • EXPERIMENTAL DESIGN: We identified genetic alterations associated with histologic progression of 36 paired meningioma samples in 18 patients using 500K SNP genotyping arrays and NF2 gene sequencing.
  • RESULTS: The most frequent chromosome alterations observed in progressing meningioma samples are early alterations (i.e., present both in lower- and higher-grade samples of a single patient).
  • In our series, NF2 gene inactivation was an early and frequent event in progressing meningioma samples (73%).
  • Chromosome alterations acquired during progression from grade I to grade II meningioma were not recurrent.
  • CONCLUSION: Meningiomas displayed different patterns of genetic alterations during progression according to their NF2 status: NF2-mutated meningiomas showed higher chromosome instability during progression than NF2-nonmutated meningiomas, which had very few imbalanced chromosome segments.
  • This pattern of alterations could thus be used as markers in clinical practice to identify tumors prone to progress among grade I meningiomas.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Dosage. Gene Expression. Gene Expression Profiling. Genotype. Humans. Loss of Heterozygosity. Male. Middle Aged. Mutation. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682713.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, Grigg A, Callahan J, Hicks RJ: Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci; 2010 Jan;17(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this prospective pilot study in patients with suspected or known brain tumour was to establish the diagnostic value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) when compared to fluorine-18 fluorodeoxyglucose (FDG) PET.
  • Twenty-five FET PET and FDG PET scans were performed on 21 consecutive patients within 24 months.
  • Final malignant pathology included 11 glioma (eight low-grade, three high grade), two lymphoma, one olfactory ganglioneuroblastoma, one anaplastic meningioma.
  • FET sensitivity was 93%, specificity 100%, accuracy 96%, positive predictive value (PPV) 100% and negative predictive value (NPV) 91%.
  • FET PET is more accurate than FDG PET for detecting malignant brain lesions, especially low-grade gliomas.
  • [MeSH-minor] Adult. Aged. Brain / pathology. Brain / physiopathology. Brain / radionuclide imaging. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Glioma / metabolism. Glioma / pathology. Glioma / radionuclide imaging. Humans. Lymphoma / metabolism. Lymphoma / pathology. Lymphoma / radionuclide imaging. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20004582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / O-(2-((18)F)fluoroethyl)-L-tyrosine; 0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


78. Trinkaus M, Vranic A, Dolenc VV, Lah TT: Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers; 2005 Jan-Mar;20(1):50-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
  • Meningiomas are, in general, slowly growing benign tumors attached to the dura mater and composed of neoplastic meningothelial (arachnoidal) cells.
  • They have a wide range of histopathological appearances and are classified, according to the aggressiveness of their growth and the risk of recurrence, as WHO grade I (benign) meningiomas, WHO grade II (atypical) meningiomas and WHO grade III anaplastic (malignant) meningiomas.
  • As invasion of normal tissue may occur in all grades, independent biological markers are needed to identify the more aggressive and recurrent meningiomas.
  • The lysosomal cysteine proteinases, cathepsins B and L, have been associated with tumor invasiveness and the aim of this study was therefore to evaluate them, together with their endogenous inhibitors stefin B and cystatin C, as potential markers for the aggressiveness of meningiomas.
  • The expression of cathepsins B and L and their inhibitors stefin B and cystatin C in 21 benign (grade I) and 9 atypical (grade II) meningiomas has been compared by immunohistochemical staining, QRT-PCR and Northern blot analysis.
  • The protein levels of cathepsins B (p=0.050) and L (p=0.019) were found to be significantly higher in atypical than in benign meningiomas.
  • Protein and mRNA levels of stefin B (p= 0.007), but not cystatin C, were significantly lower in atypical compared with benign meningiomas.
  • The expression of cathepsins and inhibitors was not different between central and peripheral meningioma tissue or between histological subtypes of meningiomas, with the exception of cathepsin L, the level of which was significantly lower in transitional meningiomas.
  • We conclude that higher protein levels of cathepsins B and L and lower mRNA levels of stefin B are potential diagnostic markers for invasive and aggressive behavior of meningiomas.
  • The diagnostic and prognostic value for relapse of meningioma needs to be confirmed in a larger population of patients.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsins / metabolism. Cystatins / genetics. Cysteine Endopeptidases / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / antagonists & inhibitors. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cathepsin L. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Cystatin B. Cystatin C. Disease Progression. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Progesterone / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832773.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CST3 protein, human; 0 / CSTB protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 88844-95-5 / Cystatin B; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  •  go-up   go-down


79. Vranic A, Popovic M, Cör A, Prestor B, Pizem J: Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery; 2010 Oct;67(4):1124-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients.
  • BACKGROUND: Since precise diagnostic criteria for atypical and malignant meningiomas (AMMs) were provided for the first time in the 2000 World Health Organization (WHO) criteria, there is only sparse information about possible prognostic factors in the group of AMMs.
  • METHODS: We analyzed 86 primary AMMs, 76 of which were atypical and 10 of which were malignant, diagnosed according to the 2000 WHO classification.
  • Brain invasion was present in 25 of 37 cases in which brain tissue was identified in the tumor specimens.
  • [MeSH-major] Brain / pathology. Meningeal Neoplasms. Meningioma. Mitotic Index. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881577.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


80. Hamm K, Henzel M, Gross MW, Surber G, Kleinert G, Engenhart-Cabillic R: Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas. Zentralbl Neurochir; 2008 Feb;69(1):14-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas.
  • OBJECTIVE: Microsurgical resection is still the treatment of choice for skull base meningiomas.
  • 87.9% of cases had benign, 7.8% had atypical and 4.3% had malignant meningiomas.
  • The other 213 patients had larger tumor volumes of up to 135 ccm or a meningioma close to optical structures.
  • Follow-up data were available in 181 skull base meningiomas and the progression-free and overall survival rates, the toxicity and symptomatology were evaluated.
  • The overall survival and the progression-free survival rates for 5 years were 92.9%, and 96.9%, respectively.
  • Tumor volumes (TV) had shrunk about by 19.7% at 6 months (p<0.0001) and by 23.2% at 12 months (p<0.01) after SRT/RS.
  • CONCLUSION: SRT and RS offer an additional or alternative treatment option with a high efficacy and few side effects for the tumor control of skull base meningiomas.
  • [MeSH-major] Meningioma / surgery. Neurosurgical Procedures. Radiosurgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Quality of Life. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393160.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement